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Research Justification
The research results presented in this book describe the quest of Cape Kingdom 
Nutraceuticals, Prof. Patrick Bouic and Prof. Barbara Huisamen to scientifically 
validate the health-promoting properties of an aqueous extract of the plant 
Agathosma. To accomplish this, they used both in vitro and in vivo models to 
understand and underscore the anecdotal information regarding the benefits of 
this product. Cell-based studies were utilised to highlight anti-inflammatory and 
anti-diabetic effects, whereas animal-based studies were utilised to confirm the 
anti-diabetic effects while further elaborating the anti-obesity properties. In 
addition, technology aimed at small animals was used to demonstrate, by means 
of blood pressure measurement, anti-hypertensive effects, while ex vivo perfused 
hearts were studied to show that this extract could also protect the heart against 
an ischaemic incident.
The research summarised in this book is novel, original and has not been published 
previously, and the results presented validate future use of this extract for the 
above-mentioned health-promoting properties. In view of the current pandemic 
of obesity and non-communicable diseases, the research results presented in this 
book will be of special interest to the scientific community and health practitioners 
interested in cardiometabolic diseases and nutraceuticals as an alternative 
treatment option. In light of the failure of many pharmaceuticals to curb non-
communicable diseases, these results are deemed of high importance.
Prof. Barbara Huisamen, Biomedical, Research and Innovation Platform, South 
African Medical Research Council, Parow, South Africa; and Division of Medical 
Physiology, Faculty of Medicine and Health Sciences, University of Stellenbosch, 
Tygerberg, South Africa 
Prof. Patrick J.D. Bouic, Division of Medical Microbiology, Department of Pathology, 
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I took great pleasure in reviewing this well-structured book on the 
medicinal use of Agathosma extracts. All the authors can 
be  commended for their contribution towards novel scientific 
evidence on the anti-inflammatory-, anti-diabetic-, anti-obesity and 
anti-hypertensive properties of this plant extract. Novel information 
is also provided on protection shown by the plant extract against 
ischaemic incidences in ex vivo perfused hearts. In the light of the 
pandemic increase in obesity and related metabolic syndrome 
diseases, as well as the international interest in phytomedicine, this 
book is expected to be well received by scientists, health 
practitioners and people interested in phytomedicine.
Agathosma is one of South Africa’s medicinal plants with 
claims of multiple healing properties. In the first chapter the 
editor provides a proper background on the plant, which is also 
known as buchu. The chapter continues with discussing other 
medicinal values of Agathosma that have been described before, 
but which were not part of the research described in this book. 
This chapter also acknowledges the hepatoxicity that has been 
found before, but the toxicity is put into perspective, which 
explains why the extract has Food and Drug Administration 
(FDA) approval for use in the food industry.
With an international growing interest in ethnomedicine, the 
publication of this book is welcomed. The strength of this well-
structured book is that it not only gives background on the plant, 
but also describes the research on the efficacy of the plant 
extract on diseases that are related to, and which form part of, 
the metabolic syndrome.
How to cite: Roux, S., 2019, ‘Foreword’, in B. Huisamen (ed.), Medicinal Effects of Agathosma 





Description: An individual Buchu branch with flowers.
Copyright: Cape Kingdom Nutraceuticals




South Africa is rich in floral biodiversity as well as cultural 
diversity. The Cape region1 of South Africa has veldt types, with 
one of the richest compositions of indigenous aromatic plant 
species in the country. One such aromatic plant is the genus 
Agathosma. There are about 150 different species within this 
genus, which derives from a greater family called Rutaceae, 
which also includes citrus plants.1 These rutacious shrubs are part 
of the Cape Floral Kingdom (fynbos) vegetation found in the 
Western Cape Province of South Africa and are particularly 
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The term ‘buchu’ is primarily derived from the Khoisan 
(indigenous people of the western region of South Africa) and 
was used for any fragrant plant that could be dried and powdered.2,3 
Therefore, it included a wide variety of aromatic plant species, 
not singling out a specific genus.2 The Khoisan tribes relied on 
these plant materials for centuries to maintain and/or promote 
good health and longevity. For the Khoisan, dried buchu was the 
mainstay of the perfume repertoire of a woman and was also seen 
as an agent of physical and mental transformation, and was 
extensively used in medicine, perfume and certain rituals.3 In that 
era, herbal remedies formed the backbone of health care and 
were the main source of medication.3 Today, the term ‘buchu’ 
refers mostly to Agathosma betulina (round-leaf buchu, also 
known as bergboegoe or short buchu) and Agathosma crenulata 
(oval-leaf buchu, also known as anysboegoe or long-leaf buchu) 
which are the most common species.1 Agathosma betulina is a 
small, multi-stemmed plant, which grows to a height of about 1 m 
in the mountains of the Western Cape Province (from Clanwilliam 
in the north to Tulbagh in the south). Agathosma crenulata is a 
single-stemmed plant and grows to a height of approximately 
2.5 m, which grows between Gouda (north) and Stanford (south) 
and as far as the Outeniqua Mountains (east). The preferred soils 
of these plants are mostly nutrient-poor, sandy soils, with low pH 
levels varying between pH 3.7 and pH 5.3. Buchu plants grow 
naturally on steep slopes, with altitudes ranging between 737 m 
and 2028 m above sea level.3
Europeans were first introduced to buchu in the 1650s, upon 
their arrival in the Cape.1 The knowledge and use of these 
plants then spread to Europe and later to America where it was 
extensively used for medicinal purposes.1 In 1821, buchu was 
officially registered in the British Pharmacopoeia and described 
for its diuretic effects and use in the treatment of genito-urinary 
tract infections.3
In the meantime, more attention was given to the organoleptic 
properties of buchu rather than its impact on health, thus 
shifting the interest towards oil extraction. Oils are obtained 
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from these plants by means of hydrodiffusion, a method called 
hydrodistillation. Buchu oils are typically used in the perfume 
industry and as flavouring agents to enhance fruit flavours.1 
Currently, buchu products are found in virtually every store, 
ranging from tea bags to water, lotions, tonics, ointments and 
brandy, and buchu is probably the best-known herb for its 
medicinal properties, both locally and internationally.4 Buchu 
oil has been approved by the US FDA; (registration number 
172.510 with a Generally Recognized as Safe [GRAS] status 
2169) and the European Union for use in foodstuffs. It is the 
only plant in the world that genetically produces the chemical 
component diosphenol,3 a 2-hydroxypiperitone molecule, 
responsible for the signature blackcurrant scent and the flavour 
of the plant.3
Farming and cutting of buchu are usually performed during 
February and March, based on the seasonal variability of the 
polyphenolic and terpenoid contents of the plants and the fact 
that buchu is not harvested during the flowering season 
(i.e.  October and November). This is to assure that the plants 
have ample time to regrow and propagate. A buchu plant, if 
properly handled, has a lifespan of up to 100 years. In the wild, 
the plant is only harvested every second or third year to ensure 
that there is enough time to regrow and seed. Currently, the 
Agricultural Research Council of South Africa, in collaboration 
with local farmers, has projects in place to monitor harvesting 
and ensure the protection of pure genetic strains of plants from 
which to propagate. This endeavour was strengthened by the 
study  of Hüsselmann,5 who used amplified fragment length 
polymorphisms to genetically characterise A. betulina and 
A.  crenulata and the possible hybrid plants that developed 
because different strains were transplanted out of their natural 
habitat. This is also important in view of the strictness with which 
the international markets are currently focussing on and buying 
organic produce. This latter movement of consumers to buy and 
use natural and organically produced products was a driving 
force for the current worldwide high demand of buchu.
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In recent years, it has also been realised that good nutrition 
plays an important role in the prevention of chronic diseases, 
such as obesity, type 2 diabetes mellitus and hypertension. The 
term ‘nutraceutical’ was first introduced by Stephen DeFelice in 
1979.6 He defined the term as ‘a food or parts of food that provide 
medical or health benefits, including the prevention and treatment 
of disease’6. To be classified as a nutraceutical, a food or an 
extract must have scientifically validated health benefits for both 
the treatment and the prevention of disease. The importance of 
this movement towards using nutraceuticals is underscored by 
numerous review papers listing, for example, plants with anti-
diabetic activity7 as well as a list of plants with potential health 
benefits published by the World Health Organization (WHO) in 
its Essential Medicines and Health Products Information Portal: A 
World Health Organization resource.8 This list of plants with a full 
description of their constituents and uses is already in its fourth 
volume.
The medicinal properties of buchu that were exploited in the 
past include antimicrobial and anti-inflammatory activities of the 
buchu oil. More recently, the inherent antioxidant capacity of 
aromatic plants has been extended to the buchu plant, as well as 
several novel aspects of health benefits of different extracts 
prepared mostly from the buchu leaves. These include analgesic 
effects, wound healing and possible effects on the male 
reproductive system, which are discussed next.
Antimicrobial activity
A number of studies have evaluated the antimicrobial activity of 
buchu using the extracted hydrodistilled essential oil from both 
Agathosma species (A. betulina and A. crenulata) to perform 
minimum inhibitory concentration assays.4 Moolla and Viljoen1 and 
Viljoen et al.10 showed that the oil was active against pathogens. 
The pathogens tested were Bacillus cereus, Staphylococcus aureus, 
Klebsiella pneumonia and Candida albicans. These results indicated 
Chapter 1
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that both extracts possess moderate antimicrobial activity4 and 
confirmed the study of Lis-Balchin et al.11 who demonstrated low 
antimicrobial activity against S. aureus, Escherichia coli and 
Saccharomyces cerevisiae. The latter study could not detect 
antimicrobial activity against either Enterococcus hirae or 
Pseudomonas aeruginosa.
Anti-inflammatory activity
Inflammation is part of our innate immune response that is 
intended to protect and eliminate the cause of cell injuries.4 During 
the initial phases of acute inflammation, there is an increase in the 
production and release of vasoactive amines and eicosanoids 
that are responsible for initiating a process aimed at neutralising 
and removing harmful agents in order to allow the healing process 
to start. An integral part of the response of the host towards a 
site of inflammation is the attraction of leukocytes to and sticking 
onto the endothelium of the microvessels. The main eicosanoids 
are formed from arachidonic acid to render leukotrienes, 
prostaglandins and thromboxane.12 Two main enzymes are 
involved in this process, lipoxygenase and cyclooxygenase, with 
the former leading to the formation of leukotrienes. Moolla and 
Viljoen1 demonstrated that buchu oil has the ability to block the 
5-lipoxygenase (5-LOX) enzyme, the key enzyme that produces 
leukotrienes, with IC50 values 50.37 ± 1.87 μg/mL for A. betulina 
and 59.15 ± 7.44 μg/mL for A. crenulata, respectively. Leukotrienes 
are known to be involved in a variety of inflammatory diseases. 
Because Viljoen et al.10 reported specifically that limonene could 
inhibit 5-LOX, the anti-inflammatory effects of the buchu oil were 
ascribed to this cyclic monoterpene that is also the major 
component in the oil of citrus fruit peel.
In 1989, Hansen published a review paper,13 highlighting that 
the formation of leukotrienes is associated with:
 • contraction of the smooth muscle and thus also the smooth 
muscle of the airways leading to asthma
Introduction and literature review
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• reduced cardiac output because of vasoconstriction 
accompanied by reduced left ventricular contractility
• increase in pulmonary arterial pressure
• possible kidney disease
• atopic dermatitis and psoriasis
• ischaemia/reperfusion injury of the brain
• inflammatory bowel disease
• arthritis. 
Hypothetically, the ability of buchu to inhibit 5-LOX should, 
therefore, be exploitable in all of these diseases; however, this 
needs to be investigated scientifically. Currently, leukotriene 
receptor inhibitors are available in the market as an adjunct 
treatment for asthma patients.
Moolla and Viljoen1 additionally reported on a double-blind 
placebo-controlled study undertaken by the Research Unit of 
Exercise and Sports Medicine, University of Cape Town, South 
Africa, where the efficacy of a topical gel containing buchu was 
tested on the inflammation caused by muscle damage. As reported 
by Lambert et al.,14 application of the gel was able to reduce 
swelling and pain in the damaged muscles. Furthermore, Cheraghali 
et al.15 showed that topical application of pulegone, a monoterpene 
found mainly in A. crenulata,16 in a vaseline and eucerin base, 
resulted in enhanced wound healing, with the significant restoration 
of stiffness and strength after both excisional and incisional 
wounds. This was accompanied by enhanced hydroxyproline 
content, implying enhanced collagen formation.
Antioxidant activity
Free radicals are highly reactive molecules containing an unpaired 
electron in an atomic orbital. Because of their nature, they can 
react with nearby stable molecules to gain an electron. In a cell, 
this could be lipids, DNA or proteins, thereby propagating free 
radical capability and damaging DNA, membrane systems and 
proteins. Within a cell, free radicals can be produced by normal 
enzymatic reactions, for example, by mitochondrial oxidative 
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phosphorylation reactions and the Nicotinamide Adenine 
Dinucleotide Phosphate (NADPH) oxidase system, or can 
be supplied from external sources such as radiation and cigarette 
smoke (review by Lobo et al.).17 The human body has complex 
systems to counteract the damaging effects of free radicals and 
ensure homeostasis by means of antioxidant defence systems 
like superoxide dismutase (SOD), glutathione peroxidase and 
catalase. Some of the best-known exogenous antioxidants are 
vitamins A and E (fat-soluble) and Vitamin C (water-soluble). In 
addition, plant phenolics from our diets play a major role in 
our  exogenous antioxidant defence system by protecting 
cells against oxidative damage. Their numerous effects are mainly 
attributed to their polyphenolic contents.18 These polyphenols 
are mostly found in teas, fruits, vegetables and spices.
Agathosma species are rich in flavonoids and various terpenes, 
one of them being the monoterpene limonene, which is thought 
to be involved in the anti-inflammatory effects of the buchu oil. 
As a component of citrus peel, limonene has been well studied 
and has a known antioxidant capacity. Despite this, studies by 
Moolla et al.1,2,10 reported on only weak antioxidant activity of the 
oil of both A. betulina and A. crenulata. Their studies corroborated 
the observations by O’Brien19 who also found a poor correlation 
between the total phenolic content of different extracts prepared 
from Agathosma and the radical scavenging activity of the 
extracts, despite the presence of quercetin, kaempferol and rutin, 
all of which have known radical scavenging properties.18,20 Most 
of the assays in the studies mentioned above were performed on 
the organic extractible fractions of the plant, but Thring et al.21 
prepared aqueous extracts of a battery of plant material, including 
leaves from buchu, to test both the anti-ageing and antioxidant 
activities. Although this extract of buchu did not perform well 
against skin ageing, as tested by anti-collagenase and anti-
elastase activities, the authors demonstrated a Trolox Equivalent 
Antioxidant Capacity (TEAC) of 11.8 μM Trolox. In addition, they 
found SOD activity of 20.49% in comparison to 85.02% of the 
positive control (SOD, at 3.33 units final volume). At the time of 
Introduction and literature review
10
writing, this was the only study that used an aqueous extract to 
test for antioxidant activity, thereby demonstrating that this 
fraction of buchu indeed contains antioxidant potential.
Benefits for the reproductive system
The extracts of Agathosma species have a long-standing 
application as a diuretic or as a treatment modality for urinary 
tract infections. As previously mentioned, this was the first 
effect registered in the British Pharmacopoeia in 1821. In 
addition, it is listed as a possible treatment option for 
prostatitis.1,2,11,22 The unique 2-hydroxypiperitone diosphenol 
found in buchu oil is said to be responsible for the diuretic 
action, although the mechanism of this action is unknown. As 
summarised by Skosana et al.,23 extracts of buchu may also be 
beneficial in the treatment of benign prostatic hyperplasia, 
inflammation of the prostate and various other urinary tract 
infections. By taking together the anti-inflammatory and 
antioxidant potential as discussed above, she concluded that 
buchu is a worthy candidate to regulate sperm function without 
having detrimental effects on the ability to reproduce. However, 
more scientific validation is required.
Analgesic properties
Scant information is available with regard to the analgesic 
properties of buchu extracts, although this should be expected 
in view of the anti-inflammatory properties of the extracts. 
However, in an elegant study bringing together physiology, 
chemistry, applied chemistry and nanotechnology, Chiguvare 
et  al.24 combined buchu leaf ethanolic extracts with silver 
nanoparticles to test possible analgesic properties. They used a 
scientifically validated mouse model and aspirin as a positive 
control in their study. In all aspects tested, the silver nanoparticle 





A ChronoscreenTM analysis of an aqueous extract of buchu 
performed by Sibelius in Oxford, UK, using both S. cerevisiae and 
C. elegans as model organisms, demonstrated a 62% increase in 
viability and a 21% improvement in median lifespan in yeast 
against an untreated control and a 33% increase in viability and 
an 8% increase in survival in the worm screen. In the yeast screen, 
this product performed better than Resveratrol. Even a 10 000 
times dilution of the neat buchu extract was still able to improve 
the viability of S. cerevisiae.
The ChronoscreenTM platform has been developed specifically 
for the analysis of compounds and nutraceuticals for drug 
discovery and product development programmes. The 
nutraceutical Resveratrol is known to prolong lifespan and retard 
the onset of age-related markers.25 It is used as a positive control 
in the ChronoscreenTM analysis.
Toxicity
The organic fractions (oil) of Agathosma contain a chemical that 
may be hepatotoxic when present in high concentrations. 
Agathosma crenulata is known to contain the monoterpene 
pulegone, while A. betulina does not.16 Pulegone is not water-
soluble and has been approved by the US FDA for use in the food 
industry (with a Flavor and Extract Manufacturers Association 
[FEMA] GRAS status and listed among the authorised synthetic 
flavouring substances CFR 21-172.515). According to European 
standards,26 pulegone has a No Observable Effect Levels (NOEL) 
of 100 mg/kg in beverages. An LC50 value of 25.91 mg/mL was 
recently reported by Raza et al.27 Some of the earlier studies that 
showed hepatotoxicity (e.g. Moorthy et al.28) used pulegone 
levels of 400 mg/kg to demonstrate significant decreases in the 
levels of liver microsomal cytochrome P-450 and haeme. 
Previously, Mizutani et al.29 proposed that the hepatotoxicity of 
pulegone was because of a metabolite formed through the 
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cytochrome P-450 system and not because of the parent 
compound. This was confirmed by Sztajnkrycer et al.,30 who 
suggested that CYP1A2 was the important isoform involved in 
pulegone metabolism. They furthermore demonstrated that 
inhibition of CYP P-450 mitigated the toxicity of pulegone 
in mice. In addition, the effects of pulegone were accompanied 
by depletion of the glutathione antioxidant system.31 The studies 
discussed above were all performed with pharmacologically high 
doses of pure pulegone.
Material used for in vivo model
The buchu oil required for the commercial market is extracted 
from the plant material and separated from the by-products 
using a steam distillation process. As the oil is distilled at low 
temperature but under high vacuum, the water used as part of 
the distillation process (cooling process) contains not only the 
more water-soluble molecules (hydrophilic compounds) but also 
some of the more volatile oil-soluble compounds usually found in 
the oil distillate. For the purposes of this research, it was decided 
to utilise the water distillate, knowing that it would contain the 
compounds of interest, albeit in a total mixture with some 
chemical identities only present in the oil.
The liquid chromatography–mass spectrometry (LC-MS) 
analysis of a representative sample of the water used, 
concentrated 180 times before analysis, shows a chromatogram 
of several molecular species as depicted in Figure 1.1. LC-MS is 
an analytical technique that combines the physical separation 
capabilities of liquid chromatography (or high-performance 
liquid chromatography) and the mass analysis capabilities 
of  mass spectrometry (MS). The analysis was performed by 
the  Central Analytical Facilities (CAF) of the University of 
Stellenbosch.
Targeted analysis using known standards revealed that such 
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quercetin and pulegone. Many other molecular species with 
unknown structures are also present in the water and could 
therefore account for the biological activity demonstrated both 
in vitro and in vivo as described in subsequent chapters.
The in vitro studies (Chapter 2) confirmed that the previously 
reported anti-inflammatory effects of Agathosma are fully 
retained in the aqueous extract utilised. In addition, cell-based 
studies indicated possible anti-glycaemic effects, paving the way 
for further preclinical studies in this regard. Chapter 3 summarises 
the data obtained in animal models on the effects of Agathosma, 
improving experimentally induced type 1 and type 2 diabetes. 
Furthermore, the aqueous extract showed both anti-obesity 
(Chapter 4) and anti-hypertensive effects (Chapter 5) in these 
animal models, thereby improving the full spectrum of the 
metabolic syndrome.
It is recognised that extrapolation of the effects observed in 
animal models to humans will need clinical trials for corroboration 
of the findings. This is especially true where pancreatic effects 
are involved, as it is known that rodent models do not have similar 
beta-cell biochemistry to that of humans.32 The results obtained 
from the current studies nevertheless substantiate the necessity 
of such clinical investigations.
The studies presented in this book were supported by Cape 
Kingdom Nutraceuticals (Pty) Ltd (contract numbers: S003211, 
S002594) who also supplied the aqueous extract of buchu. 
They were not involved in the studies or the interpretation of 
any of the results, and no conflict of interest is declared by the 
authors.
CHAPTER 2
Evaluation of buchu extracts 
in vitro: Evidence of its 
anti-glycaemic and anti-
inflammatory properties
Description: Buchu seedlings in a nursery.
Copyright: Cape Kingdom Nutraceuticals




For many years, the water distillate resulting from the oil 
production phase of buchu was sold in the health market as 
herbal water. Many anecdotal testimonials were received from 
users of the buchu water, stating that the consumers with either 
insulin resistance or type 2 diabetes were managing their blood 
sugar levels (glycaemia) better since the intake of the product. 
Evaluation of buchu 
extracts in vitro: 
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It was therefore decided to investigate this in vitro by making 
use of cell lines that depend on an anti-glycaemic agent such as 
additional insulin or the drug metformin to survive in the 
presence of excess glucose during the culture phase. The cells 
normally grow in the presence of physiological concentrations 
of the glucose. However, if glucose is added to their culture 
medium in the presence of any agent/drug that can be actively 
transported across the cell membrane, then the uptake of the 
added glucose or its utilisation is vastly improved compared to 
that of the non-treated cells.
This in vitro model was used for testing the ability of both the 
buchu oil distillate and the water condensate to impact glucose 
utilisation of two specific cell lines as discussed here.
Furthermore, the historical use of the plant extracts related by 
the indigenous people of South Africa was for the management 
of conditions involving an inflammatory process, including cystitis 
and arthritis, among others. For this reason, we decided to use 
in vitro models of human inflammatory responses to investigate 
the effects of the various fractions obtained from the water 
condensate to evaluate this biological effect. We made use of 
human peripheral blood cells which, when triggered by biological 
response modifiers, upregulate (increase) the expression of 
membrane adhesion molecules (which aid during the chemotactic 
attraction of the innate cells of immunity), undergo an enzymatic 
response to produce the reactive and protective cellular response 
called the respiratory response (generation of O2
–) or release 




Two specific cell lines (Chang Liver cells and 3T3-L1 cells) were 
obtained from the American Type Culture Collection (ATCC) and 
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kept as long-term cultures in RPMI 1640 medium supplemented 
with 5% foetal bovine serum (FBS) and cultured at 37 °C and 5% 
CO2. These cell lines have been reported to be useful in vitro tools 
when evaluating herbal extracts for their potential anti-diabetic 
properties of novel molecules with promise for in vivo evaluation.1,2
The reported concentration of glucose in the RPMI medium, 
according to the manufacturer, is 2 mg/mL. The cells were cultured 
with the normal RPMI, FBS-supplemented medium, and on the 
day of experimentation, the cells were taken out of the culture 
flask, washed using sterile pure RPMI medium and placed back 
into the culture for 2 h to ‘starve’ the cells of essential nutrients. 
During this ‘starvation period’, various drugs or buchu extracts 
were co-incubated with the cells for 2 h. Then, the cells were 
seeded into 96-well microtiter plates at 100 000 cells/well; the 
medium containing increased glucose concentrations (additional 
1 mg/mL, hence a total nominal concentration of 3 mg/mL) was 
added to all wells. Wells that contained cells having received 
added glucose-spiked medium but no added drug or extract were 
included as ‘control wells’. The drugs or the extracts were therefore 
present throughout the total culture period.
Following a further overnight cell culture, the microtiter plate 
was centrifuged and the medium supernatant was removed for 
glucose measurement. Hence, the glucose measured in the 
‘control wells’ served as 100%, and the drug-treated wells’ 
concentrations were compared to those values. If the drug or the 
buchu preparations enhanced the glucose uptake and utilisation, 
then those wells would demonstrate a lower glucose concentration 
when compared to controls (results were expressed as percentage 
above control).
Peripheral blood cells from human  
blood
Blood was collected from volunteers by phlebotomy; 
anticoagulated samples (using Li-heparin tubes) were collected 
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and cells were prepared from the blood by density gradient 
centrifugation on Ficoll. The cells were recovered and washed 
several times using sterile RPMI medium before being placed 
into the culture in 96-well microtiter plates for 16 h. During this 
period, the cells were activated using bacterial endotoxin 
(Lipopolysaccharide [LPS], at 1 μg/mL) in the presence or 
absence of the buchu extracts. The plates were incubated for 
16 h after which the culture supernatants were harvested by 
careful pipetting. Those wells that had not received any 
investigational compounds were regarded as maximal response 
wells, and all other wells were compared with those wells. The 
results were expressed as a percentage of maximal response. 
The release of the inflammatory cytokines tumour necrosis 
factor-alpha (TNF-α) or interleukin-6 (IL-6) into the culture 
supernatants was measured by enzyme-linked immunosorbent 
assay (ELISA) techniques.
Further testing of the buchu extracts was conducted in vitro 
against the granulocytes (neutrophils and monocytes) by 
investigating their ability to mount the so-called respiratory burst 
(generation of the radical O2
–). This was measured using flow 
cytometry and fluorescently labelled substrates. Similarly, the 
expression of adhesion molecules at the surface of these cells 
was measured post-activation in the presence or absence of the 
extracts.
Drugs or buchu extracts used
Insulin was purchased as a ready-for-use formulation from our 
local medical supplier. This was in pre-filled graduated syringes 
of 1 mL volume equivalent to 80 IU of the drug. The final 
concentration used was a 1 μM solution.
Metformin was purchased from Sigma-Aldrich (St Louis, 
Missouri) as a lyophilised powder. At the time of use, this was 
dissolved in 100% methanol as suggested by the distributor. The 
final concentration used was 1 μM.
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The buchu extracts used were either the pure oil distillate 
(coded as CK_Oil) or the water condensate (coded as CK_H2O); 
the water recovered during the distillation process to obtain the 
oil from the leaves was back-extracted using ethyl alcohol 
followed by drying under reduced pressure to finality and 
subsequently re-suspended into 100% methanol. The stock 
solution was made up in methanol at 600 μg/mL concentration. 
For the testing, this was diluted using distilled water before its 
addition to the wells containing the cells. Final dilutions used 
were 150X, 300X or 600X diluted from the 600 μg/mL stock 
solution.
Results
Effects on glucose metabolism
The commercial ELISA assay used yielded reproducible results, 
with a dynamic range of 0.031 μg/mL – 1.5 μg/mL and a correlation 
coefficient (R2) of 0.993.
The culture supernatants recovered post 24-h incubation 
showed that the ‘control cells’ having received the increased 
(spiked) glucose (but no drug or extracts) still had 2.13 mg/mL 
of glucose present, implying that the cells were able to take up 
some of the extra added glucose and to metabolise this even in 
the absence of any added drug or buchu extract. However, 
those wells that had been treated with metformin had further 
decreased the glucose compared to the control wells, implying 
that these stimulated the uptake and metabolism of the added 
glucose.
Figure 2.1 shows a typical experiment using the Chang Liver 
cell line. The positive control (metformin at 1 μM) exhibited 23% – 
25% increased glucose uptake. In parallel, the buchu oil showed a 
dose-dependent effect from 0.15 ppm to 0.6 ppm, with the wells 
having received 600 ppm of the oil showing the highest increase 
in glucose uptake and metabolism. However, it never reached the 
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same level of increased uptake or metabolism compared to the 
positive control metformin. It is interesting that when using this 
cell line, the CK-H2O extract showed no significant effects on the 
glucose metabolism by these cells.
The results obtained using the 3T3-L1 cell line are shown in 
Figure 2.2. Once again, the addition of insulin at 1 μM led to the 
increased uptake (by almost 35%) of the glucose added to the 
culture medium (positive control). In parallel, the addition of 
the CK-H2O extract displayed an increase of 35% – 40% uptake of 
the glucose. No effects were measurable when the CK_Oil was 
used in these cells.
Anti-inflammatory activity
Firstly, when human peripheral blood cells were activated 
in vitro using LPS, the release of TNF-α and IL-6 was clearly 
evident in the culture supernatants as measured by ELISA 
(100% maximal response). Surprisingly, the addition of the 
buchu water condensate (which was back-extracted) to the 
cells led to significant inhibition of such cytokines, implying 
the ability of the fractions to inhibit the in vitro response (see 
Figure 2.3).
Similar results were obtained when the release of IL-6 was 
evaluated, suggesting that chronic inflammatory responses could 
be inhibited when buchu is added to this in vitro model.
Secondly, further experiments were conducted in parallel 
whereby the ability of the buchu extracts to inhibit the 
upregulation of adhesion molecules (CD11b/CD18) on innate cells 
of immunity (namely granulocytes) was evaluated. For these 
experiments, the expression of these surface molecules was 
measured using fluorescent-labelled monoclonal antibodies and 
flow cytometry.
Once again, we demonstrated that when human cells are 
activated in vitro to express higher levels of the membrane 
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adhesion molecules CD11b/CD18, the addition of the buchu 
extracts significantly inhibited this physiological response, 
implying that the buchu was able to inhibit the acute onset of 
inflammation (Figure 2.4). This representative experiment clearly 
shows that the buchu extract has more pronounced effects on 
the expression of the CD11b/CD18 membrane molecule of 
neutrophils compared to that expressed by monocytes; a clear 
dose-response effect is demonstrated by dilutions of 1:400 up to 
1:3200 tested.
Thirdly, during the initial phase of neutrophil functions, the 
internalised organism or particle is destroyed by an oxygen-
dependent process, which ultimately leads to the generation of 
oxygen radicals (O2
–). These radicals are protective when they 
are generated in the cytoplasm of the cell in that it kills the 
bacterium. However, when these are released to the external 
F1 - F5, correspond to the fractions; LPS, Lipopolysaccharide; TE, total extract prior to further fractionation.
Note: Results are expressed as a percentage of maximum (cells in the absence of any added fractions).
FIGURE 2.3: The in vitro effects of various buchu water condensate fractions on the release 
of TNF-α in the culture supernatants of human peripheral blood cells activated by the 
bacterial endotoxin LPS.



















medium, it can damage healthy tissues in the vicinity of the 
phagocytic cell.
The ability of buchu extracts to influence the generation of 
oxygen radicals was measured by flow cytometry. As shown in 
Figure 2.5, it is evident that at different dilutions of the water 
extract, the oxidative burst (respiratory burst) of neutrophils was 
significantly inhibited by the watery distillate dilutions (from 
1:400 to 1:3200 dilutions).
Discussion
The in vitro model used to investigate the possibility that buchu 
extracts could enhance the uptake and/or metabolism of glucose 
by two well-described cell lines proved to be easy to use and 
yielded results, which implied that the self-reported anecdotes 
from consumers that their blood glycaemia was better managed 
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when using these products were correct. Although no mechanism 
of action of the extracts could be deduced from this model, it 
remains an interesting observation nonetheless. Furthermore, at 
this stage, we have no scientific proof of which compound(s) 
could be responsible for this observation, as the extracts used 
contain numerous molecules or chemical entities.
The model clearly showed that buchu oil extract (CK_Oil) had 
more pronounced effects on the Chang Liver cell line, with little 
or no effects seen when the CK_H2O was tested in parallel. The 
converse was seen when the 3T3-L1 cell line was used as a 
model – the CK_H2O had a significant effect on the 3T3-L1 cell 
line, whereas no effect was seen when the oil was tested. These 
cell lines have different origins – the 3T3-L1 cells are of adipose 
tissue origin, whereas the Chang cells are of hepatocyte origin. 
Even in this model, we were able to demonstrate differences in 
sensitivities to well-described anti-glycaemic agents, such as 
FIGURE 2.5: Respiratory burst by neutrophils and monocytes in the presence or absence of 















































insulin versus metformin. The Chang Liver cells were responsive 
to the added metformin, whereas the 3T3-L1 cells responded to 
the added insulin. It is therefore not surprising that the buchu oil 
showed differential effects on the cell lines (similar to the watery 
extract of the buchu).
The above results were sufficient evidence for us to take these 
into an in vivo model (as reported in subsequent chapters). To 
our knowledge, this is the first time that a natural herbal extract 
has been shown to control glycaemia in vitro as well as in vivo in 
an animal model. Agothosma remains a rich source of natural 
compounds with potent biological activities reported by the 
indigenous folk.
As far as the anti-inflammatory properties of the buchu are 
concerned, the in vitro model utilising human peripheral blood 
cells clearly demonstrated and supported the anecdotal use of 
this herbal extract by the indigenous peoples for the management 
of inflammatory conditions (such as cystitis and arthritis). Several 
assays were used to demonstrate this potent activity. The 
respiratory burst of neutrophils and monocytes was significantly 
inhibited and, simultaneously, the expression of adhesion 
membrane molecules was inhibited. Both of these physiological 
responses are implicated during the acute inflammatory phase. 
Furthermore, the extracts inhibited the release of potent cytokines 
such as IL-6 and TNF-α, both of which are directly implicated in 
the pathogenesis of chronic inflammatory conditions. It is also 
important to note that when tested in vitro, the two species of 
the buchu used (round and oval) yielded different results, with 
the oval leafed buchu species showing more potent inhibitory 
activity. The water condensate sold as a herbal remedy contains 
both species and therefore accounts for the effective anti-
inflammatory properties reported by consumers. The anti-
inflammatory property of Agathosma was previously reported by 
other groups, showing the ability of buchu to inhibit the 
5-lipoxygenase enzyme that ultimately leads to leukotriene 
synthesis.3
Evaluation of buchu extracts in vitro
28
Once again, we are unable to predict which bioactive 
molecules within these extracts are responsible for the anti-
inflammatory potency. To isolate and identify individual chemical 
entities in these extracts presents challenges beyond the current 
infrastructure of the researchers.
Acknowledgements
The author would like to thank W. Kriek, Synexa Life Sciences 





Description: Cultivated Buchu not flowering.
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According to the WHO Factsheet, November 2017,1 the current 
estimation of people with diabetes has risen to an astounding 
422 million worldwide. This information was taken from 
projections of disease performed by Mathers and Loncar.2
Diabetes is a severe and chronic disease, which occurs when 
the pancreas does not produce enough insulin3 or when the body 
is unable to utilise the available insulin effectively. Both these 
conditions result in increased blood glucose levels that may over 
time lead to severe damage to the heart and vascular system, 
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Three types of diabetes are recognised: 
1. type 1 diabetes (T1D), formerly known as insulin-dependent or 
juvenile diabetes
2. type 2 diabetes (T2D), previously termed non- insulin-
dependent or adult-onset diabetes
3. gestational diabetes. 
The third is a condition where pregnancy results in increased 
blood glucose levels, but mostly this is resolved after delivery.
Type 1 diabetes is an autoimmune disease and has an active 
genetic component. It is characterised by the destruction of the 
pancreatic b-cells, leading to insulin deficiency.4 It accounts for 
5% – 10% of all diabetes; however, as reviewed recently,5,6 its 
prevalence is increasing globally, at a rate of 2% – 3% per year. 
Although previously seen as a juvenile form of diabetes, it is 
currently estimated that more than 40% of all new cases of T1D 
occur in people over the age of 30 years.7
The aetiology of T1D informs that the pancreatic islet cells are 
progressively destroyed by autoantibodies. It is currently 
a disease without a cure, and although the understanding of the 
disease’s progression has grown, there is no known preventative 
measure for disease development. All prevention trials to date 
have failed,6 and the only current treatment option is daily insulin 
injections. However, the interesting concept of pre-T1D with a 
staging of disease development has been suggested by the 
American Diabetes Association.8 This staging includes an 
important presymptomatic stage characterised by a steady 
decline in functional b-cell mass. Even at the beginning of the 
symptomatic phase, there is still a portion of functional b-cells 
available.
Type 2 diabetes describes the majority of people with diabetes 
and has a strong link with obesity and metabolic factors. However, 
the risk factors for the development of T2D also include genetic 
factors, ethnicity, physical inactivity, smoking and age, but is 
largely the result of excess bodyweight, especially abdominal fat 
Chapter 3
33
accumulation and physical inactivity.9 In addition, all these risk 
factors not only predispose to the development of gestational 
diabetes but also imprint a future risk of both obesity and T2D on 
the genome of the mother, which is carried into the next 
generation.
In the development of obesity-related T2D, the pre-diabetic 
state is characterised by peripheral insulin resistance (an inability 
to utilise available insulin in the body). Insulin is the primary 
stimulus for the muscle to utilise available blood glucose, the liver 
to stop producing glucose (de novo glucose synthesis) and the 
fat tissue to store any leftover glucose into fat. If this system 
malfunctions, the resultant increased blood glucose levels prompt 
a further increase in insulin secretion by the pancreas as glucose 
uptake and metabolism are the primary stimuli for insulin 
secretion. The pre-T2 diabetic state is therefore characterised by 
normal glucose levels but high insulin levels. The tipping point is 
when the pancreatic b-cells are not able to compensate further. 
The most recent paradigm for the progressive loss of function 
of the b-cell population lies in the concept of dedifferentiation of 
the b-cells caused by the post-prandial rise in blood glucose in 
the insulin-resistant state.10 Like all cells in the body, b-cells are 
derived from embryonic stem cells during the developmental 
stages.11 During this process, certain transcription factors and 
their downstream gene clusters are activated or repressed.10 With 
dedifferentiation, this process is driven backwards, leaving the 
pancreas with a lower concentration of mature b-cells and more 
precursor cells. The differentiated state of the cell populations is 
recognised by the specific transcription factors expressed at a 
given time point.
At the tipping point, the blood glucose levels start to rise to 
pathologic levels, turning pre-diabetes and insulin resistance into 
T2D. It has been shown that this happens when 50% of the b-cell 
population is not functional anymore.12 Because of this long, 
asymptomatic prelude to the development of obesity-related 
T2D, many of the detrimental consequences, for example, 
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cardiovascular complications, had a 5–10-year period to develop. 
Type 2 diabetes is recognised as a chronic disease state with no 
cure because of the destruction of mature, insulin-secreting 
pancreatic b-cells, although by a different mechanism. Prevention 
is therefore no longer an option at the time of diagnosis, but 
treatment is.
With these concepts of T1D and T2D in mind, we performed 
preclinical evaluations of the effectiveness of an aqueous extract 
of Agathosma (buchu) to act as a treatment option in both 
types of diabetes, or to act as a preventative option against the 
development of obesity-related T2D.
Methods
Ethical considerations
In all instances, only male, outbred Wistar rats, obtained from 
Charles Rivers Laboratories, Inc. (Wilmington, MA) and bred 
within the Central Research Facility of the University of 
Stellenbosch, were used. These rats were age- and weight-
matched at the onset of experimentation. All animals were 
housed at the University of Stellenbosch Central Research 
Facility, which provided a simulated environment of the animals’ 
natural habitat, exposing them to a temperature-controlled 
room (22 °C–24 °C) and a 12-h light–dark cycle.13 The animals 
had free access to water and food for the duration of the 
experiment. Control animals were fed normal rat chow, while 
the diet-induced obesity (DIO) or high-fat diet (HFD) animals 
were given an obesogenic diet as indicated. Specific groups in 
both diabetic models were treated with buchu water. The 
projects were approved by the Ethics Committee of the 
University of Stellenbosch (Faculty of Health Sciences – protocol 
number SU-ACUM11-00003) and conformed to the principles 
revised in the South African National Standard for the Care and 
Use of Animals for Scientific Purposes (South African Bureau of 




The well-known streptozotocin (Stz) model to induce T1D by 
chemical destruction of the pancreatic b-cells was utilised.14 We 
have previously determined that a dose of 40 mg/kg of Stz 
injected in an adult rat will result in proportional destruction of 
b-cells, thereby representing the pre-T1D state.15 The Stz-induced 
model is deemed a suitable model for studying the complications 
of T1D because of the following: 
1. continued b-cell derangement continues after Stz is 
eliminated from the body because of the established 
hyperglycaemia
2. Stz-induced diabetes can be reversed by insulin treatment, 
which indicates that the b-cell population can respond to 
treatment and has the ability to regenerate
3. Stz-induced diabetes can be ameliorated or alleviated by 
administration of phytochemicals.16 
It must however be recognised that this is a chemically induced 
model, while the development of human T1D is an autoimmune 
disease, as previously discussed. It is therefore possible that 
effects of alleviation by the administration of any substance may 
always be overridden by the immune response.
Adult male Wistar rats (200 g – 250 g) were injected with a 
single intraperitoneal dose of Stz in citrate buffer (pH 4.5) at 
40 mg/kg bodyweight. Vehicle-injected animals represented the 
controls. This amount of Stz results in a 50% ablation of b-cells.15 
Blood glucose levels, measured via a drop of blood obtained 
from a tail prick using a handheld glucometer (GlucoPlusTM, 
Montreal, Canada), were monitored daily for 3 weeks. Animals 
that spontaneously recovered normal blood glucose levels were 
removed from the groups. T1D animals were categorised into 
two groups, namely, those (1) with unfasted blood glucose levels 
below 20 mmol/L and (2) those with unfasted blood glucose 
levels between 20 mmol/L and 30 mmol/L. Stz-injected animals 
received the diluted buchu water from the 3-week time point. 
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After 14 weeks, the animals were fasted overnight to obtain 
fasting blood and perform an Intraperitoneal Glucose Tolerance 
Test (IPGTT).
Type 2 diabetes
A DIO model was used to render the animals insulin resistant. 
It is known that rats do not develop T2D as a result of obesogenic 
diets without a mechanism to also ablate some of the b-cell 
population. It is also postulated that rats do not form and 
deposit islet amyloid polypeptide in the pancreatic b-cells.17 
The animals in our experiments therefore represent the pre-
diabetic state. In the course of the studies described in this 
chapter and Chapters 4 and 5, two different variations of the 
diet were utilised. The composition of the DIO diet is described 
in this chapter and represents a diet high in sugar but not in fat 
(see Table 3.1).
Animals on this diet (DIO) do not develop hypertension; 
therefore, the diet was changed to also induce hypertension in 
the animals (described in Chapters 4 and 5). The main 
difference between these two diets lies in the elevated fat 
content as well as the higher fructose content available in the 
HFD. The composition of the HFD is provided in Chapter 4. The 
feeding regime of the animals was identical in all 
experimentation.
Young rats weighing 190 ± 10 g (6–7 weeks old) were divided 
into two groups, namely, a group receiving normal rat chow 
and  a  group receiving rat chow supplemented with sugar and 















Control 4.8 3 17.1 34.6 6.6 1272
DIO 4.6 10 9.4 45.8 27.7 1173
Source: Analysis performed by Microchem Lab Services (Pty) Ltd.
CHO, carbohydrate content; DIO, diet-induced obesity.
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condensed milk18,19 (DIO) for a period of 16 weeks. Buchu water 
treatment was commenced after 8 weeks when the animals had 
gained substantial weight and already presented with insulin 
resistance.20 Food intake and the weight of the animals were 
monitored throughout the experimentation.
To ensure that the buchu species were well blended over the 
16-week period, multiple 1.5 L sealed buchu water bottles were 
received from Cape Kingdom Nutraceuticals and diluted on a 
weekly basis.
The animals had free access to food, undiluted water or 
diluted buchu extract water, and the intake was monitored 
throughout the 16-week period. The extract dilution was 
calculated according to the equivalent surface area dosage 
conversion factors as described by Freireich et al.,21 assuming 
that an adult human (60 kg) would consume 250 mL of the water 
per day, while a rat weighing 250 g would consume a mean of 
30 mL water per day.
Fifteen weeks after the onset of the diet period, the animals 
were fasted overnight, whereafter baseline glucose was 
determined and 1 mL of fasting blood was collected from the 
carotid artery. The blood was left on ice to clot, followed by serum 
collection and storage at −80 °C. Fasting serum was used to 
determine insulin levels.
The animals were left to recuperate from the metabolic insult 
for 1 week before experimentation.22
The animals were anaesthetised by intraperitoneal injection 
with 160 mg/kg bodyweight of sodium pentobarbital and 
monitored until deep anaesthesia, as determined by the lack of 
the pedal and eye reflexes.
Bodyweight was recorded, and death was induced by 
exsanguination. Unfasted blood was collected in SGVac gel 
serum collection tubes and left to clot on ice, followed by 
serum collection. Serum was stored at −80 °C for biochemical 
analyses.
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The pancreata were harvested, snap-frozen in liquid nitrogen 
and stored at −80 °C for biochemical analyses. In addition, 
ventricular cardiomyocytes were prepared to determine the 
effects on myocardial insulin resistance.
Assays performed
  On both type 1 diabetes and type 2 
diabetes models
 Intraperitoneal glucose tolerance test
An intraperitoneal glucose tolerance test was routinely performed 
to determine whole-body glucose tolerance.23 The animals were 
fasted overnight, whereafter a blood sample was obtained from 
a tail prick to determine the blood glucose level. At the same 
time, 1 mL of fasting blood was collected from the carotid artery; 
serum was separated and stored at −80 °C. Then, a dose of 1 g 
sucrose / kg bodyweight was injected intraperitoneally, and the 
disappearance of glucose from the blood was monitored over a 
2-h period.
  Only on type 1 diabetic animals
 Daily monitoring of blood glucose levels
The blood glucose levels of these animals were followed daily for 
the full duration of 14 weeks by collecting blood samples from 
a tail prick in the morning and reading the value on a handheld 
glucometer.
  Only on type 2 diabetic animals
 Insulin radioimmunoassay
A commercially available Radioimmunoassay (RIA) kit (Coat- 
A-Count®; Siemens Medical Solutions Diagnostics, Los Angeles, 




 C-peptide enzyme-linked immunosorbent assay
A commercial rat-sensitive ELISA kit was obtained from Abcam 
Ltd (Cambridge, UK) and used according to the manufacturer’s 
instructions to determine the C-peptide levels in the stored 
serum. C-peptide levels are an indication of newly secreted insulin 
from the pancreatic β-cells.
 Cardiomyocyte glucose uptake
  Preparation of cells
Calcium-tolerant adult ventricular myocytes in an unstimulated 
state were prepared as described previously.19 After isolation, 
myocytes were suspended in buffer A containing mmol/L 
HEPES 10, KCL 6, NaH2PO4 0.2, Na2HPO4 1, MgSO4 1.4, NaCl 128, 
pyruvate 2, glucose 5.5, 2% BSA (fraction V, fatty acid-free) plus 
1.25 mmol/L calcium, pH 7.4. The cells were left for 1 h–2 h under 
an oxygen atmosphere on a gently shaking platform to recover 
from the trauma of isolation. This procedure routinely rendered 
more than 80% of viable cells as measured by Trypan blue 
exclusion. After recovery, the cells were allowed to settle into a 
loose pellet, the supernatant was aspirated and the cells were 
washed twice with, and suspended in, a suitable volume of 
substrate-free buffer A (buffer B).
  Determination of 2-deoxy-d-3[H] glucose (2DG) uptake
Cardiomyocytes (~0.5 mg protein) were assayed in a total volume 
of 750 μL of oxygenated buffer B (pH 7.4) as described previously.19 
The cells were pre-incubated for 15 min in a shaking water bath 
(37 °C) with or without phloretin (400 μM) for measurement of 
non-carrier-mediated glucose uptake. Each experimental series 
was incubated with or without 10 nM insulin for 30 min after which 
glucose uptake was initiated by addition of 2-deoxy-d-[3H] 
glucose (1.5 μCi/mL; final concentration 1.8 μM). The glucose uptake 
was allowed to progress for a further 30 min before the reaction 
was stopped by adding 50 μL phloretin to give a final concentration 
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of 400 μM. The cells were then microfuged for 1 min and the pellet 
was dissolved in NaOH (sodium hydroxide). An amount of 50 μL 
of this solution was used to assay protein by the method of Lowry 
et al.,24 while the rest was counted for radioactivity. The results 
were calculated as pmole 2DG/mg protein/30 min.
  Pancreatic tissue western blotting of transcription 
factors
Frozen sections of pancreatic tissue were pulverised in a 
liquid nitrogen pre-cooled mortar and pestle and extracted 
in a standard Radioimmunoprecipitation Assay (RIPA) buffer 
containing in mM: Tris-HCl (pH 7.4) 20; EGTA 1; EDTA 1; NaCl 150; 
b-glycerophosphate 1; tetrasodium-pyrophosphate 2.5; sodium 
orthovanadate 1 with 1% Triton-X100, 10 μg/mL leupeptin, 10 μg/mL 
aprotinin and 50 μg/mL PMSF. The tissue was homogenised using 
a PolyTron PT10 homogeniser twice for 5 s at setting 4 and left 
on ice for 15 min to fully digest. The lysate was centrifuged at 
15 000 rpm in a microfuge at 4 °C and the pellet was discarded. 
The protein content of the supernatant was determined according 
to the method of Bradford25 and diluted to equal protein per 
sample. A three-times concentrated Laemmli sample buffer was 
added in a 1:2 v/v ratio and the sample was boiled for 5 min.
Sixty micrograms of protein were subjected to Polyacrylamide 
Gel Electrophoresis (PAGE) using a BioRad Mini Protean III 
system, and the resultant separated proteins were transferred to 
Polyvinylidene Difluoride (PVDF) membranes. Transfer and equal 
loading were confirmed by Ponçeau Red reversible stain.26 The 
non-specific binding sites on the membranes were blocked for 
2 h at room temperature with 5% fat-free milk dissolved in TBS-
Tween. They were then incubated overnight at 4 °C with the 
suitable primary antibody, diluted according to the manufacturer’s 
instructions. After rinsing thoroughly with TBS-Tween the next 
morning, the membranes were exposed for 1 h at room temperature 




The signal of the specific antibodies bound to the target 
protein was captured by exposure to an enhanced 
chemiluminescent reagent reacting with the horseradish 
peroxidase to render a signal captured on film. The film was laser 
scanned and analysed using computer software (Un-Scan-It, 
SilkScientific, Orem, UT 84059, USA).
Statistical analyses
The statistical significance of results was analysed using GraphPad 
Prism 6. A one-way or two-way analysis of variance (ANOVA) was 
used as applicable, followed by a Bonferroni post hoc analysis 
to indicate how groups differed. Daily monitoring of blood 
glucose levels and the intraperitoneal glucose tolerance curves 
were analysed using a repeated measure two-way ANOVA. 
A p-value of less than 0.05 was considered statistically significant.
Results: Type 1 diabetes
The ingestion of the aqueous extract of buchu, given as a 
treatment option to animals with partially ablated pancreatic 
b-cells and presenting with blood glucose levels of less than 
20 mmol/L, completely normalised their random blood glucose 
levels, as shown in Figure 3.1 and Figure 3.2. The more robust 
ablation, leading to blood glucose levels of more than 20 mmol/L, 
was significantly lower than the untreated controls.
Results obtained from the IPGTT is shown in Figure 3.3 and 
demonstrate that whole-body glucose tolerance in animals that 
ingested buchu water after partial ablation of the b-cell population 
with Stz was normalised in both the groups with a low percentage 
of ablation of b-cells (24 h < 20 mmol/L) as well as a high 
percentage of ablation of b-cells (24 h > 20 mmol/L).
Figure 3.4 shows a compilation of the blood glucose values 
obtained after 120 min of monitoring from the time of onset of 
the IPGTT procedure. This shows that both groups of animals 
treated with buchu water were now able to effectively clear 
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Stz, streptozotocin.
Note: The blood glucose levels of the different groups of animals at week 3 before the commencement of 
the buchu water treatment and at week 14 before termination of the animals. 
n = 8–10 per group 
*, vs. control; #, vs. < 20; $, vs. Stz; ^^, vs. 3 weeks < 20 
**,^^,$$, p < 0.01; ****,####, p < 0.0001
































Note: Treatment with buchu water commenced at week 3.
n = 8–10 per group
*, vs control; #, vs < 20; $, vs Stz; ^^, vs 3 weeks < 20
*, #, $, p < 0.05; ##, $$, p <0.01; ***, p <0.001; ****, p < 0.0001
Effect of buchu, p < 0.0001 
FIGURE 3.1: Blood glucose levels of the animals were measured on a weekly basis by collecting 
a drop of blood from a tail prick and reading the value using a handheld glucometer.
Control, untreated
Stz, untreated
Stz, buchu week 3 (24h:<20)
Stz, buchu week 3 (24h:>20)




































Note: Blood glucose levels were by means of blood samples from a tail prick over a 2-h period.
n = 8–10 per group 
p < 0.0001
FIGURE 3.3: An IPGTT was performed after an overnight fast at week 14 of the treatment 
protocol, with point 0 on the graph representing the fasting value before administration of 
a 50% sucrose solution at 1 g/kg bodyweight.























Stz, buchu week 3 (24h:<20)
Stz, buchu week 3 (24h:>20)
Control
Stz, streptozotocin. 
n = 8–10 per group 
****, p < 0.0001 vs STZ
FIGURE 3.4: Blood glucose values obtained in the intraperitoneal glucose tolerance test 2 h 
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glucose from the circulation within 2 h in comparison to the 
untreated Stz group. The observed blood glucose values of the 
treated groups did not differ from those of the control animals 
that received no Stz and no buchu water.
Results: Type 2 diabetes
Figure 3.5 shows the bodyweight of the groups of animals that 
were fed either control rat chow (control) or a diet supplemented 
with sugar and condensed milk to induce hyperphagia (DIO) for 
a period of 16 weeks. There was no significant increase in 
bodyweight of the DIO animals over the course of the 16 weeks. 
However, ingestion of buchu water resulted in a significant effect 
of lowering bodyweight gain by animals in both the control and 
DIO groups.
Figure 3.6 shows that the DIO diet resulted in abdominal 
obesity in the animals as they presented with a significantly 
DIO, diet-induced obesity. 
Note: A two-way ANOVA indicated a significant effect of buchu water.
n = 10-16 per group 
p = 0.018 
FIGURE 3.5: Bodyweight of animals from the four different groups indicating the mean 
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larger amount of accumulated visceral fat. In addition, the DIO 
animals ingesting buchu water did not accumulate this additional 
visceral fat.
Figure 3.7 depicts the fasting blood glucose levels of the 
groups of animals at 15 weeks after onset of the obesogenic diet. 
These are the values obtained at the start of the IPGTT. The 
animals on the DIO diet presented with significantly elevated 
fasting glucose levels. After the 8-week treatment period, the 
fasting blood glucose values of the DIO + buchu group did not 
differ significantly from values obtained from either control or 
control + buchu-treated animals.
The results obtained by performing an IPGTT on control and DIO 
animals treated with buchu water from week 8 to week 16 of the 
respective diets are shown in Figure 3.8. This graph confirms 
the potential of the buchu water to normalise whole-body glucose 
tolerance, showing that after 8 weeks there were no significant 
DIO, diet-induced obesity; IPGTT, Intraperitoneal Glucose Tolerance Test. 
Note: After the euthanasing of the animals, the fat depots in the visceral cavity were dissected and 
weighed. This included the renal and epididymal fat pads. 
p = 10–16 per group 
***, p < 0.001; ****, p < 0.0001
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DIO, diet-induced obesity; IPGTT, Intraperitoneal Glucose Tolerance Test. 
Note: Animals were fasted overnight to perform an IPGTT, and blood glucose levels were determined from 
a drop of blood collected from a tail prick and measured using a handheld glucometer.
***, p < 0.001; ****, p < 0.0001




























DIO, diet-induced obesity; IPGTT, Intraperitoneal Glucose Tolerance Test. 
n = 3–8 per group
Effect of DOI, p < 0.0001; Effect of buchu on DOI, p < 0.01 
##, p < 0.01, DIO + Buchu wk 8 vs Control and Control + Buchu wk 8; ****, p < 0.0001, DIO vs Control and 
control + Buchu wk 8; ####, p < 0.0001, DIO + Buchu Wk 8 vs DIO 
FIGURE 3.8: IPGTT curves were generated as previously described and obtained from 
animals fed a control diet and those fed the obesogenic DIO diet, treated with buchu water 
or tap water as control.



























Control + Buchu wk 8
DIO + Buchu wk 8
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differences between control animals and DIO animals that ingested 
buchu water from week 8 onwards. The 2-h values obtained through 
these graphs furthermore showed that the blood glucose values 
of the DIO + buchu animals were significantly lower than the values 
of the DIO animals and did not differ from that of control animals.
Figure 3.9 shows the results of the effects of ingestion of 
buchu water as a treatment option in pre-type 2 diabetic animals 
on insulin sensitivity at organ level using isolated ventricular 
cardiomyocytes. The ability of the cells to respond with glucose 
uptake to a concentration of 10 nM insulin was measured. In both 
control and DIO animals ingesting buchu water, insulin sensitivity 
at organ level was significantly enhanced. It can therefore be 
concluded that the ingestion of buchu water without a change in 
ingestion of an obesogenic diet was able to enhance the glucose 
utilisation at a given level of insulin in peripheral insulin-sensitive 
tissue.
DIO, diet-induced obesity. 
Note: Ventricular cardiomyocytes of hearts from control and DIO animals, with or without an 8-week 
treatment period, with buchu water were isolated by ex vivo collagenase perfusion. Cells were stimulated 
with 10 nM insulin as described in the ‘Methods’ section, and the accumulated DG was calculated per 
milligram protein over a 30-min period. 
n = 3–7 per group 
p < 0.04 
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Because of the observed effects of buchu water ingestion on 
glucose homeostasis in models of both type 1 and type 2 pre-
diabetes, we investigated possible pancreatic effects. This was 
prompted by results showing enhanced insulin secretion in the 
DIO animals after ingestion of buchu water, as shown in 
Figure 3.10a. The secretion of insulin was further substantiated 
by an increase in the levels of C-peptide observed 
(Figure  3.10b). In addition, pancreatic transcription factors 
were analysed by western blotting. The two chosen 
transcription factors, Musculoaponeurotic Fibrosarcoma 
Homolog A (Maf A) and pancreatic duodenal homeobox 1 
(Pdx-1), were significantly downregulated in the DIO animals 
(Figure 3.11). The ingestion of buchu water by DIO animals in 
combination with the obesogenic diet resulted in significant 
upregulation of both Maf A and Pdx-1. In addition, the overall 
effects of buchu ingestion, as indicated by a two-way ANOVA 
analysis, showed a highly significant effect. The enhanced 
expression of these transcription factors is an indication of 
b-cell neogenesis, probably by means of redifferentiation of 
pancreatic progenitor cells or acinar cells.27
DIO, diet-induced obesity. 
FIGURE 3.10: (a) Insulin levels of fasted serum obtained at the time of performance of 
the intraperitoneal glucose tolerance test were determined using a Coat-A-Count RIA 
(125I radioimmunoassay) (n = 5–7). (b) The C-peptide levels were determined using a rat-





























DIO, diet-induced obesity. 
(a) p = 0.01; (b) p = 0.007
*, p < 0.05; **, p < 0.01
FIGURE 3.11: (a & b) Lysates were prepared from pancreata frozen at the time of 
euthanasia of the animals from the different experimental animal groups. They were 
analysed by western blotting and specific commercially available antibodies against 
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Discussion
The question that was posed was whether the aqueous extract 
of Agathosma as supplied by Cape Kingdom Nutraceuticals 
possessed any anti-diabetic properties as a treatment option. 
The research project tested this question by utilising two 
different animal models of diabetes simulating type 1 and type 
2 diabetic populations. In both populations, it is recognised that 
there are stages of the disease that can be classified as pre-
type 1 and pre-type 2 diabetes.8 The animal models used were 
manipulated to represent these so-called pre-stages. In T1D, 
this allows a remainder of pancreatic b-cells that has the 
potential to respond to treatment. If all b-cells were ablated, as 
is the scenario in end-stage T1D, manipulation would be 
impossible. Similarly, the DIO rat model, induced by feeding a 
diet rich in sugar and fatty acids, results in animals that are 
insulin resistant but, according to their fasting blood glucose 
levels, not type 2 diabetic.
From the results obtained, it is evident that buchu water was 
able to alleviate the pre-type 1 diabetes condition, in all instances, 
to very near normal levels when used as a treatment option. The 
animals presented with either >20 mmol/L or <20 mmol/L fasting 
blood glucose values and were grouped accordingly. This is also 
representative of the measure to which the pancreas was 
damaged. Highly significant statistical results were obtained 
showing normalisation of blood glucose levels in the <20 mmol/L 
group and a significant improvement in the >20 mmol/L group 
(Figure 3.1 and Figure 3.2). The IPGTT used to measure 
postprandial insulin responses to remove glucose from the 
circulation (Figure 3.3 and Figure 3.4), clearly demonstrated 
normalisation in both groups at the clinical relevant 2-h post-load 
values.28 This is deemed a novel and important demonstration in 
that the aqueous extract of buchu has the ability to be used as a 
treatment option in newly diagnosed pre-type 1 diabetic patients. 
However, it must again be stressed that results obtained in an 




Anti-hyperglycaemic effects of buchu water were further 
substantiated in the diet-induced obese animals (Figure 3.7 and 
Figure 3.8). In addition, it was observed that the ingestion of 
buchu water resulted in a loss of intraperitoneal fat (IP fat). The 
effects of buchu water on fat tissue will be discussed in detail in 
Chapter 4.
To ascertain that the effects of buchu water on whole-body 
insulin sensitivity, as measured by the IPGTT assay, were also 
carried over to organ and cell level, we used myocytes isolated 
from the ventricles of the hearts of the animals after treatment. 
This is a sensitive measure to confirm the effects of buchu water 
on the glucose utilisation of peripheral insulin-sensitive tissue 
that is known to be responsible for the removal of post-prandial 
glucose from the circulation.29 Figure 3.10 shows that the 
ingestion of buchu water as a treatment of pre-diabetes was 
able to significantly improve the ability of cardiomyocytes to 
accumulate glucose after stimulation with insulin. The exact 
cellular mechanism that was involved in this improvement was 
not elaborated.
As it was further noted in the DIO animals that the ingestion of 
buchu water stimulated insulin secretion (Figure 3.10a and b), we 
measured pancreatic transcription factors that are associated 
with the regeneration of pancreatic b-cells.
Musculoaponeurotic fibrosarcoma homolog A (Maf A) is a 
transcription factor of the basic leucine zipper family.30 Maf A is a 
unique transcription factor expressed during late pancreatic 
development and is restricted to pancreatic b-cells.31 It is known 
to regulate insulin gene expression.32,33 In addition, it has been 
shown that the transcriptional activity of Maf A has a synergistic 
interaction with Pdx-1 that will enhance gene expression.34
Pancreatic duodenal homeobox 1 protein is essential for early 
pancreatic development and b-cell survival.35 Pdx-1 expression is 
restricted to pancreatic progenitor cells during early development, 
but later it becomes restricted to the b-cells. Low expression of 
Pdx-1 has been linked to a decline in b-cell population and 
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impaired glucose tolerance.35 This decline in Pdx-1 is postulated 
to be because of enhanced DNA methylation induced by 
hyperglycaemia.36 Eventually, this leads to b-cell death via 
apoptosis. When substantial b-cell loss occurs, it will result in 
permanent endocrine deficiency and irreversible diabetes.27 It 
has been shown that patients suffering from T2D have a 
significantly lower b-cell population than healthy persons.27 
Current research to remedy this situation has a strong focus on 
different strategies to produce new endocrine islet cells. 
Preclinical studies have already shown Pdx-1 expression as 
a promising candidate in this arena as it was found that, when 
Pdx-1 progenitor cells were transplanted into mice, some of these 
cells differentiated into functional b-cells which could reverse 
diabetes.36,37 Furthermore, it was found that combination 
expression of Pdx-1 and Maf A, among others, could efficiently 
convert pancreatic acinar cells into b-like cells when these 
transcription factors were supplied to mouse pancreata through 
adenoviral vectors.38,39
In light of the fact that both T1D and T2D are the result of 
substantial b-cell loss, and currently there is no treatment option 
to remedy or stop this loss, the results obtained in this study are 
of great importance. It is categorically stated by Zhou and 
Melton27 that:
[I]f pharmacological means can be found to ‘redifferentiate’ the 
dedifferentiated b-cells, it could constitute a new therapeutic 
approach for diabetes and may be viewed as a distinct form of 
regenerative therapy. (p. 355)
The obesogenic diet fed to the rats in this study resulted in a 
significantly lower expression of both Maf A and Pdx-1, which is 
indicative of a loss of b-cell mass. The ingestion of buchu water 
as a treatment option significantly enhanced the expression of 
both these transcription factors, indicating an increase in 
functional b-cell mass. It must, however, be reiterated that human 
T1D is an autoimmune disease where the regeneration of 
pancreatic b-cells may be counteracted by the effects of the 
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autoantibodies and that this concept needs to be further explored 
through clinical trials.
It is recognised that different polyphenols in an extract, such 
as the one used in this study, have very low levels. In addition, the 
bio-availability of most of these polyphenols is also very low. In 
the past, this has repeatedly posed the question of how orally 
ingested polyphenols may change physiology. In this regard, a 
new paradigm has emerged, centring on the ability of nutrition 
to alter the inherent microbiome of the host ingesting any form 
of food.40 This microbiome consists of various bacteria, viruses, 
protozoa and fungi41 and has an intricate relationship with 
the physiology of the host. It plays a major role in the way by 
which any substance ingested influences the physiology and 
pathophysiology of the host.41,42
With regard to effects on pancreatic regeneration, 
γ-aminobutyric acid (GABA) has been recognised as a facilitator 
to reprogramme pancreatic b-cells. Treating mice with GABA 
resulted in a significant increase in pancreatic b-cell mass.43 As 
reviewed by Foster et al.,44 a definite link between the gut 
microbiome and the regulation of brain neurotransmitters has 
repeatedly been demonstrated. Bravo et al.,45 for example, 
showed that probiotic modulation of the gut microbiota of mice 
could induce neurochemical changes that were relayed through 
the vagus nerve connections. It was also shown that the gut 
microbiota can act as an endocrine organ by directly producing 
metabolites that are transferred to the circulation. Among these 
neurotransmitters, both serotonin and GABA were identified, and 
it was demonstrated that oral ingestion of Lactobacillus increased 
GABA levels also in the brain.46 If the aqueous extract of 
Agathosma utilised in this study could induce the gut microbiome 
to secrete substances such as GABA that have been shown to act 
on the most important transcription factors involved in pancreatic 
redifferentiation, it could explain our findings of enhanced b-cell 
neogenesis despite the low levels of polyphenols that can be 
expected to reach the circulation.
Anti-diabetic properties of buchu
54
These findings are deemed novel and may indeed lead to the 
development of pharmacological means to redifferentiate 
b-cells and treat both pre-type 1 and pre-type 2 diabetes. 
Retrospectively, determination of serotonin and GABA levels in 
the circulation could have been performed to substantiate these 
arguments.
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According to a WHO report, more than 1.9 billion adults worldwide 
are currently overweight and more than 650 million of these 
individuals are obese.1 Obesity is associated with several health 
consequences, including cardiovascular diseases (CVDs) and 
T2D.2 These conditions cause premature death or substantial 
disability, resulting in an economic burden.
Obesity is defined as excessive fat accumulation, traditionally 
described as a result of an imbalance between energy intake 
versus energy expenditure. According to the first law of 
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thermodynamics, energy in will be equal to energy out plus 
stored energy. This excess energy is stored in adipocytes, causing 
hyperplasia (increase in fat cell number) and hypertrophy 
(increase in fat cell size).3 However, the problem that isocaloric 
diets with different composition ratios of fat, carbohydrate and 
proteins do not always result in similar weight gain or weight loss 
was addressed in the carbohydrate-insulin model of obesity 
suggested by Ludwig and Ebbeling.4 The rationale of this model 
of obesity lies in the fact that a carbohydrate load is the strongest 
stimulus of insulin secretion, which, in turn, stimulates lipogenesis 
in fat cells. On the other hand, a low intake of carbohydrates will 
limit insulin secretion, thereby counteracting fat deposition and 
obesity. This concept can clinically explain how the composition 
of a diet, although isocaloric, by effects on the hormonal 
regulatory systems, can either cause obesity or have no effect on 
weight gain.
With diet management, however, adipocyte size can 
decrease, but their numbers are constant during adulthood.5 
Hypertrophied adipocytes lead to the activation of several 
macrophage-attracting chemokines followed by macrophage 
recruitment.6,7,8 Macrophages secrete cytokines, including tumour 
necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6), causing 
an inflammatory cascade and thereby inducing insulin resistance 
in the mature adipocytes.6,9,10,11 Activated macrophages block 
pre-adipocyte differentiation, resulting in a larger population of 
hypertrophied fat cells (Figure 4.1). According to the adipose 
tissue expandability hypothesis, this leads to the development 
of insulin resistance within the adipose mass, while adipose 
depots that consist of new or small adipocytes are associated 
with improved insulin sensitivity.6,12 Insulin-resistant adipocytes 
cause an elevation in Free Fatty Acids (FFAs) release and 
further macrophage activation, forming a vicious circle. It is 
postulated that insulin resistance in adipose tissue precedes 
the development of whole-body insulin resistance and lipid 
accumulation in other organs.6,13 It has also been shown in humans 
that even in non-obese individuals, adipocyte insulin resistance, 
Chapter 4
59
characterised by altered adipokine profiles, is associated with 
adipocyte hypertrophy and whole-body insulin insensitivity.9 In 
addition, Bremer et al. found that subcutaneous fat depots of 
patients suffering from metabolic syndrome were associated 
with increased biomarkers of both insulin resistance and low-
grade inflammation.14 Peroxisome proliferator-activated receptors 
(PPARs) are important regulators of glucose and lipid storage and 
oxidation. In adipose tissue, PPARγ is an important transcription 
factor controlling adipogenesis and adipocyte differentiation.6,15 
Peroxisome proliferator-activated receptor α is associated 
with regulating the expression of genes controlling fatty acid 
oxidation.16 Sterol regulatory element-binding proteins (SREBPs) 
regulate lipid homeostasis by acting as transcription factors for 
lipid synthesis.15,17 Ferreira et al. demonstrated the upregulation of 
both PPARγ and SREBP-1 (also termed Srebf1) in adipose tissue 
of high-fat-fed mice, while overexpression of Srebf1  in adipose 
tissue of mice resulted in adipocyte hypertrophy.18,19
Source: Adapted from Virtue and Vidal-Puig6 and composed using Microsoft PowerPoint.
FFA, free fatty acids; TNF-α, tumour necrosis factor-alpha; IL-6, interleukin-6
FIGURE 4.1: Adipose tissue expandability.
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Because of the effects of ingestion of buchu water on blood 
glucose handling, bodyweight and, especially, the intraperitoneal 
(IP) fat weight, this study was conducted to document changes 




In this study, the animals were randomly divided into a control 
group and a HFD group and kept on the respective diets for 
16 weeks (Table 4.1). This specific diet renders the animals both 
insulin resistant and hypertensive, which is further elaborated on 
in Chapter 5. All other aspects of handling the animals were 
similar, as described in Chapter 3.
In this study, both renal and gonadal fat pads were removed 
to determine the weight. A specific portion of fat with a piece of 
muscle attached was dissected from the renal pads for 
histological examination of fat cell size. About 50 mg of fat was 
collected in Ribonucleic Acid (RNA) later® (Thermo Fischer 
Scientific, Waltham, MA USA 02451) for real-time polymerase 
chain reaction (PCR).
Histology
Fat was cryo-fixed and eosin-stained for the histological 
determination of fat cell size. Three areas (1 mm × 1 mm) per 
sample were selected using low magnification, a Zeiss Axioskop 2 

















Control 4.8 3 17.1 34.6 6.6 0.5 1272
HFD 27.9 6.4 14.6 29.5 13.3 11 1829




microscope with AxioVision v4.7 software and an Axiocamera. 
Each area was enlarged 10 times and then the diameter of every 
cell in the specific area was measured. Data from the different 
groups of animals were compiled and statistically analysed.
Biochemical analyses
ELISA kits (Abcam®, Cambridge, UK) were used to determine 
unfasted serum leptin, adiponectin, TNF-α and IL-6 levels. Insulin 
levels were determined using fasting serum and a RIA coat-a-count 
assay (Siemens Medical Solutions Diagnostics, Los Angeles, CA).
Polymerase chain reaction
Total RNA was extracted from 50 mg of fat in RNA later® using 
Qiazol reagent and purified using the RNeasy Mini Kit, according 
to the manufacturer’s instructions (Qiagen). The RNA concentration 
and purity were determined spectrophotometrically using the 
Nanodrop, ND-1000 (Nanodrop Technologies, Thermo Fischer 
Scientific, Waltham, MA 02451, USA) and integrity was determined 
using the Bioanalyser 2100 (Agilent Technologies, Santa Clara, CA 
95051, USA).
DNase-treated RNA (Turbo DNA-free DNase, Life Technologies, 
Thermo Fischer Scientific, Waltham, MA 02451, USA) was reverse-
transcribed to cDNA using the high-capacity reverse transcription 
kit (Life Technologies). Real-time quantitative PCR was performed 
in a total volume of 10 μL using cDNA templates and pre-
formulated Taqman gene expression assays (Table 4.2) according 
to the manufacturer’s protocol (Life Technologies). The cycling 
conditions were 50 °C for 2 min, 95 °C for 10 min, followed by 
40 cycles of 95 °C for 15 s and 60 °C for 1 min. Quantification was 
carried out on the 7500 real-time PCR system (Life Technologies). 
The default settings for the threshold cycle (Ct) and baseline 
were used. The mRNA levels of each gene were normalised to 
those of the housekeeping genes b-actin (ActB) and hypoxanthine 
phosphoribosyltransferase 1 (Hprt).
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Total liver cholesterol, liver triglycerides, 
plasma phospholipids and plasma 
triglycerides analysis
Plasma and liver samples were analysed for concentrations of 
lipids, including total cholesterol, triglycerides and phospholipids.
Total cholesterol, triglycerides and phospholipids 
concentrations were determined using enzymatic colorimetric 
kits (LabAssayTM Cholesterol [catalogue number 294-65801], 
LabAssayTM Triglyceride [catalogue number 290-63701] and 
LabAssayTM Phospholipid [catalogue number 296-63801]; Wako 
Chemicals, Neuss, Germany) and using a SPECTRA-max Plus 384 
spectrophotometer with SoftMax Pro 4.8 microplate data 
acquisition and analysis software (Molecular Devices [US/
Canada]; Labotec Industrial Technologies [Pinelands, South 
Africa]). The inter-assay coefficients of variation for these 
analyses were all less than 3%.
Livers were stored at −80 °C for lipid analysis. Liver tissue was 
homogenised on ice, using a Vir Tis hand shear (The VirTis Company, 
Gardiner, NY, USA), in 10 volumes of 75 m mM phosphate buffer 
containing 0.5 M EDTA (Sigma-Aldrich, Johannesburg, South 
Africa), pH 7.4. Extraction of lipids was carried out by the Bligh and 
Dyer method,20 a modified method of Folch et al.21 Briefly, lipids 
were extracted into a monophasic mixture of chloroform and 
TABLE 4.2: Taqman gene expression assay.
Taqman gene expression assay Assay number
Srebf1 Rn01495769_m1





PPAR, Peroxisome proliferator-activated receptors.
Note: Taqman gene expression assays were performed according to the manufacturer’s protocol 
(Life Technologies). The mRNA levels of each gene were normalised to those of the housekeeping genes 
β-actin (ActB) and hypoxanthine phosphoribosyltransferase 1 (Hprt).
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methanol (Merck [Pty] Ltd South Africa, Cape Town). This mixture 
was finally separated into two phases, one of which was the organic 
phase containing the purified lipids. This layer was dried under 
nitrogen gas, after which it was dissolved in chloroform and divided 
into aliquots, dried once again under nitrogen headspace and stored 
at −80 °C. For lipid analyses, the extracts were solubilised in ethanol 
(Merck [Pty] Ltd South Africa, Cape Town) and Triton X-100 (Sigma-
Aldrich [Pty] Ltd South Africa, Cape Town), and this was followed 
by the addition of physiological saline. This was used for the 
determination of total cholesterol, triglyceride and phospholipid 
concentrations in the liver samples. Liver cholesterol, triglyceride 
and phospholipid concentrations were determined using the 
enzymatic colorimetric kits as described for plasma above.
Statistical analysis
All data were statistically analysed using GraphPad Prism 5. All 
values are given as mean ± standard error of the mean (SEM). 
A two-way ANOVA, followed by a Bonferroni post hoc test, was 




Table 4.3 summarises the biometric parameters and daily food 
and water consumption of the animals. The HFD significantly 
increased the animals’ bodyweight from 381.3 g ± 9.5 g to 451.8 g 
± 15.1 g (n = 10/group; p < 0.001) and IP fat from 8.6 g ± 0.4 g to 
24.5 g ± 2.7 g (n = 10/group; p < 0.0001) when compared to the 
controls. However, buchu water consumption resulted in less 
weight gain (from 451.8 g ± 15.1 g to 394.1 g ± 14.0 g; n = 10/group; 
p < 0.01) and less IP fat gain (from 24.5 g ± 2.7 g to 15.9 g ± 1.3 g; 
n = 10/group; p < 0.01) in the HFD animals. The effect of buchu 
consumption on lowering bodyweight gain was further indicated 
as highly significant (p = 0.003).
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Furthermore, similar analyses of IP fat accumulation showed 
that the HFD had a significant effect (p < 0.0001), while the effect 
of buchu consumption on lowering IP fat content was significant 
with p = 0.007. These changes were not associated with 
differences in the amount of food consumed by the animals; 
however, the HFD has a higher caloric density compared to the 
control diet (Table 4.1). A slightly diminished buchu extract intake 
was noted in the control animals, but not in the HFD animals.
The HFD animals presented with increased fasting blood 
glucose levels (p < 0.01), while buchu consumption had a 
significant overall effect on blood glucose levels (p < 0.01) and 
prevented the rise in blood glucose in the HFD animals (p < 0.05).
Adipocyte hypertrophy
In Figure 4.2, data are summarised to show that the HFD animals 
presented with enlarged fat cells (p < 0.0001), while the ingestion of 
buchu in the HFD animals decreased the fat cell size (p < 0.0001). 
Then again, fat cells in the control animals were overall significantly 
larger after buchu ingestion (p < 0.001).
TABLE 4.3: Biometric parameters of different animal groups.
Biometric parameter Control Control + buchu HFD HFD + buchu
Bodyweight (g)
n = 10/group
381.3 ± 9.5 363.2 ± 5.5 451.8 ± 15.1*** 394.1 ± 14.0##
IP fat weight (g)
n = 10/group
8.6 ± 0.4 8.7 ± 0.4 24.5 ± 2.7**** 15.9 ± 1.3##
Blood glucose (mmol/L)
n = 5/group
6.2 ± 0.1 6.0 ± 0.1 7.3 ± 0.2** 6.2 ± 0.2#
Insulin (mU/mL)
n = 5/group
16.6 ± 3.3 11.8 ± 4.7 21.8 ± 3.8 12.2 ± 0.5
Food intake (g/rat/day)
n = 20/group
21.4 ± 0.5 20.4 ± 0.4 21.7 ± 1.0 19.3 ± 0.7
Water intake (mL/rat/day)
n = 20/group
33.8 ± 0.9 28.7 ± 0.9* 29.7 ± 1.7 30.4 ± 1.0
HFD, High-fat Diet; SEM, Standard Error of the Mean; IP, Intraperitoneal.
Note: Data are expressed as mean ± SEM using two-way ANOVA (n = 5–20). The effect of buchu on bodyweight: 
p = 0.003; IP fat: p = 0.007; and blood glucose levels: p < 0.01. The effect of HFD on IP fat: p < 0.0001.
*p < 0.05 versus control; **p < 0.01 versus control; ***p < 0.001 versus control; ****p < 0.0001 versus 




Blood serum indicated that buchu ingestion had an overall 
significant effect on lowering leptin levels (p = 0.0003, 
Figure 4.3a). This was accentuated by significantly lower leptin 
levels in the HFD animals (p = 0.0023). No significant differences 
were observed in the adiponectin (Figure 4.3b), TNF-α 
(Figure 4.3c) and IL-6 (Figure 4.3d) levels.
Transcription factors
According to PCR analyses of the fat tissue, the HFD elevated 
the mRNA levels of PPARγ (p < 0.05, Figure 4.4a), while ingestion 
of buchu lowered these levels to control values (p < 0.05). The 
overall effect of the HFD on the mRNA of Srebf1 was also 
indicated as significant (p = 0.05, Figure 4.4c). These levels 
were not affected by the ingestion of buchu. Peroxisome 
proliferator-activated receptor α showed no significant changes 
(Figure 4.4b).
HFD, high-fat diet. 
Note: Histological examination of fat cell size with n = 3–5 biological replicates analysed with an n-value of 
650–1050 individual cells per group was performed and the data were compiled. 
****, p < 0.0001
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Total liver cholesterol, liver triglycerides, 
plasma phospholipids and plasma 
triglycerides
Liver analysis indicated that treatment with buchu significantly 
decreased total cholesterol levels in both the control and HFD 
animals (p = 0.03). Furthermore, buchu treatment decreased 
plasma phospholipids with borderline significance (p = 0.07) in 
both animal groups, and plasma triglycerides in the HFD animals 
(p = 0.03) (see Figure 4.5).
HFD, high-fat diet. 
Note: Values are given as mean ± SEM (n = 5–8 biological replicates per group). Analyses were performed in 
triplicate. The overall effect of buchu on leptin levels was significant (p = 0.0003).
FIGURE 4.3: Biochemical markers leptin, adiponectin, TNF-α and IL-6. (a) Plasma leptin, 
(b) adiponectin, (c) TNF-α and (d) IL-6 levels from fasted buchu-treated and untreated animals 



















































The current pandemic of obesity is a known risk factor for several 
non-communicable diseases, including cardiovascular disease, 
T2D and various cancers. Treatment strategies include lifestyle 
changes, drugs and bariatric surgery. Lifestyle changes have 
proved to be difficult to adhere to; drugs have at best modest 
benefits, while bariatric surgery, although successful in affecting 
weight loss, has serious long-term consequences.22,23 Nutraceutical 
therapies have been explored with various degrees of success in 
HFD, high-fat diet. 
Note: mRNA levels were normalised to the housekeeping genes β-actin (ActB) and hypoxanthine 
phosphoribosyltransferase 1 (Hprt). Additionally, a two-way ANOVA indicated the effect of the HFD on 
Srebf1 levels to be significant, with p = 0.05. 
n = 4 biological replicates per group
*, p < 0.05 
FIGURE 4.4: Transcription factors PPARγ, PPARα and Srebf1. For (a) PPARγ, (b) PPARα 
and (c) Srebf1 determination, total RNA was extracted from 50 mg of fat in RNAlater® for 
quantitative real-time PCR analysis.
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this field and, if scientifically validated, can supply a readily 
available and safe alternative to pharmacotherapy. Therefore, in 
this study, we tested the anti-obesity potential of an aqueous 
extract of buchu, a product currently commercially available.
The Agathosma plant, especially A. crenulata, contains one 
possible hepatotoxic substance, pulegone.24 Pulegone, however, 
is not water soluble and has been approved by the US FDA for use 
HFD, high-fat diet. 
Note: These were determined using commercially available assays (n = 3–5 biological replicates per group). 
A two-way ANOVA indicated that buchu had an overall positive effect on total cholesterol levels (n = 0.03) 
and plasma phospholipids (p = 0.07, borderline significance). Buchu also significantly decreased plasma 
triglyceride levels in the HFD animals (p = 0.03). 



















































in the food industry (with a FEMA GRAS status and listed among 
the authorised synthetic flavouring substances CFR 21-172.515). 
The no-effect level of pulegone in beverages is 100 mg/kg.25 The 
buchu extract contained 74.22 mg/L ± 1.1 mg/L pulegone, which is 
well below the acceptable level indicated by the FDA and the 
LC50 value of 25.91 mg/mL.26 Buchu-treated animals in our study 
would have ingested a maximum of 1.7 mg/kg/day of pulegone 
and showed no observable signs of hepatotoxicity according to 
liver cholesterol and triglyceride analyses (Figure 4.5).
The water of buchu-treated animals was replaced with a four 
times dilution of the aqueous buchu extract. This rendered a 
concentration in mg/L of diosmin (0.0005), quercetin (0.007), 
hesperidin (0.001) and rutin (0.0035), of which the animals 
consumed a mean of 30 mL per day. The ingestion of these 
bioflavonoids was therefore extremely low. Despite this, the HFD 
buchu-treated animals presented with significantly less IP fat 
weight gain and lower blood glucose values when compared to 
HFD-untreated animals (Table 4.3). In view of the adipose 
expandability hypothesis6 and the known effects of bioflavonoids 
on obesity,27,28,29 we examined changes brought about in the fat 
depots of the animals to understand the lesser weight gain.
As endocrine organ, fat secretes certain adipokines, such as 
leptin and adiponectin. In obese individuals, increased leptin 
levels increase the macrophage phagocytic activity, along with 
their production of pro-inflammatory cytokines, resulting in 
decreased small adipocyte formation.5,8 As shown in Figure 4.2, 
the HFD resulted in increased adipocyte size, while buchu 
ingestion resulted in significantly smaller adipocytes, 
accompanied by significantly lower leptin secretion.
Leptin acts as an appetite suppressant by inhibiting 
neuropeptide Y via negative feedback. However, our study 
documented no difference in the amount of food consumed by 
the animals (Table 4.3), therefore indicating that, in the buchu-
treated HFD animals, the lower leptin secretion was because of 
smaller adipocytes, as larger cells secrete more adipokines.11
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Buchu ingestion significantly attenuated blood glucose levels 
in both animal groups, indicating the improvement of insulin 
sensitivity (Table 4.3).
Thus, buchu ingestion in the HFD animals decreased adipocyte 
size and leptin levels, thereby increasing insulin sensitivity and 
pre-adipocyte formation12 (Figure 4.2 and Figure 4.3a).
Adipogenesis and lipogenesis are regulated by multiple 
transcription factors coding for different enzymes modulating fat 
deposition and lipolysis. To further elucidate the anti-obesity 
effects of buchu, we determined the mRNA levels of three 
regulators of adipogenesis and fatty acid oxidation: PPARγ, 
PPARα and Srebf1 (Figure 4.4a–c). No changes were observed in 
PPARα levels. Peroxisome proliferator-activated receptor γ has 
long-chain fatty acids as endogenous ligands and, as also found 
in this study, is known to be increased in adipose tissue following 
a HFD.18 In accordance with the findings in mice fed with HFD,17,19 
the transcription factor Srebf1, which is known to be involved in 
lipid synthesis, was also elevated in this study and associated 
with adipocyte hypertrophy.
Peroxisome proliferator-activated receptor γ (PPARγ) 
expression is regulated, among others, by the b-catenin pathway, 
which, in turn, is regulated by Wnt-GSK-3b signalling.30 As GSK-3 
is overexpressed in adipose tissue of obese mice,31 it can be 
expected that b-catenin levels are low, leading to increased 
PPARγ levels. The increased insulin sensitivity of the adipose 
tissue after buchu ingestion may therefore lead to the decrease 
in PPARγ levels via normalisation of inhibition of GSK-3. It is also 
known that Sirt1 promotes fat loss by repressing PPARγ through 
acetylation32; however, Sirt1 expression was not determined in 
this study. In contrast to the decrease in PPARγ levels induced by 
buchu ingestion in the HFD animals, we observed no significance 
in the control animals’ PPARγ levels, but found an increase in 
adipocyte hypertrophy. This may be explained by an observation 
by Ferreira et al.18 that diet composition differentially affects 
adipocyte hypertrophy. In addition, despite this small increase in 
adipocyte size, no increase in the IP fat deposition was detected.
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Reverse cholesterol transport (RCT) refers to the process 
where cholesterols from the peripheral tissues are returned to 
the liver via the plasma.33
The first step entails the movement of peripheral cholesterol 
and phospholipids to the pre-high-density lipoprotein (HDL) via 
the ATP-binding cassette transporter (ABCA1). Following this, 
the cholesterol present on the pre-HDL is converted by the 
Lecithin-cholesterol Acyltransferase (LCAT) enzyme to 
cholesteryl esters, which are stored in the core of the HDL. 
Consequently, the cholesteryl esters will be exchanged for 
triglycerides from other lipoproteins, for example, Very Low-
density Lipoproteins (VLDL) and Low-density Lipoproteins (LDL) 
through the cholesteryl ester transfer protein (CETP). The mature 
HDL will bind to the scavenger Receptor class B type 1 (SRB1) 
present on the liver surface, followed by the release of cholesteryl 
esters. The cholesterol will be converted into bile and transferred 
to the intestine for excretion.34,35
Interestingly, in rats and mice, RCT is altered because of a 
deficiency in the sequences coding for functional CETP 
activity.36 Thus, because of this deficiency, the plasma 
cholesterol, phospholipid and triglyceride levels of rats will be 
more accurate when measured in the plasma, as compared to 
the liver.
In this study, buchu decreased (with borderline significance) 
plasma phospholipids in both the animal groups and plasma 
triglyceride levels in the HFD animals (Figure 4.5c and d). Both 
these results are indicative of decreasing the risks associated 
with the metabolic syndrome.
Although it is recognised that the known bioflavonoids in 
the buchu extract, especially hesperidin and quercetin, have the 
ability to regulate the levels of PPARγ and Srebf1,27,29,36 the 
concentrations of these substances in even the original, undiluted 
buchu extract are so low in comparison to the concentrations 
used in these studies that, in isolation, they cannot be deemed to 
elicit the physiological effects observed.
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Conclusion
We conclude that the buchu extract tested in this study has 
beneficial effects as nutraceutical to counteract obesity, with 
all the accompanying health benefits of less weight gain. The 
exact mechanisms of how this is accomplished are possibly 
multifactorial, but include insulin sensitisation of fat cells. The 
extract may contain a hitherto unrecognised substance that may 
have elicited the observed changes, or the combination of 
bioflavonoids may be responsible.
Limitations of the study
Limitations of this study include: 
 • inflammatory mediators (TNF-α and IL-6) were only 
determined in circulation and not in the adipose tissue itself
• Sirt1 expression levels were not determined, which may have 
shed more light on the mechanisms involved
• as the study was conducted on the prevention of weight gain, 
a further study should address the buchu extract as a treatment 
option.
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Cardiovascular disease (CVD) is currently the leading cause of 
mortality in the world, resulting in approximately 17.3 million 
deaths annually, with 80% of these deaths occurring in low- and 
middle-income countries.1,2 Both obesity and elevated blood 
pressure (BP) increase the risk of developing CVD, renal failure 
and stroke, thereby further increasing the risk of mortality from 
CVD.2 Hypertension is classified as the leading preventable cause 
of death worldwide3 and is causally linked to stroke, myocardial 
infarction, end-stage renal disease, congestive heart failure, 
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statistics show an overall 55% incidence of hypertension and 
25%  of pre-hypertension. Hypertension is defined as Systolic 
Blood Pressure (SBP) ≥140 mm Hg and/or Diastolic Blood 
Pressure (DBP) ≥90 mm Hg; pre-hypertension is defined as SBP 
between 120 mm Hg and 139 mm Hg and/or DBP between 80 mm 
Hg and 89 mm Hg in the absence of a diagnosis of hypertension 
or treatment with medication for high BP.4
Despite global efforts to combat hypertension, rates of control 
of the disease remain very low. Given the continued significant 
health and economic burden on low- and middle-income 
populations, there is an urgent need to address the problem by 
way of novel approaches.2
One such approach utilises the anti-hypertensive effects of 
polyphenols found in plant extracts.5,6,7 We tested the efficacy of 
the aqueous extract of Agathosma to lower BP and to protect the 
heart using obese, hypertensive Wistar rats. In previous chapters, 
we have already discussed the significant effects of obesity and 




Hypertension was induced by feeding randomly selected animals 
(6–7 weeks old) a diet consisting of normal rat chow supplemented 
to contain 40% saturated fat, 10% fructose, 10% casein and 1% 
cholesterol for 14 weeks (HFD).8 These were the same animals 
from which the fat depots were harvested, analysed and described 
in Chapter 4.
Diuretic activity
At the commencement of treatment with the buchu water 
and again at the end of the treatment, in this specific set of 
experiments, groups of animals were placed individually in 
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metabolic cages to collect 24-h urine production as a measurement 
of diuretic activity.
Blood pressure measurement
A non-invasive computerised tail-cuff system (Kent Scientific 
Corporation, CT, USA) was used to measure BP. Rats were trained 
for 2 weeks before the commencement of data collection. The 
animals were placed on a warming platform (35 °C) within a 
restrainer fitted with a black nose cone. It was previously shown 
that temperature fluctuation of the tail may affect the measurement 
of BP.9 Each session included two sets of five measurements so 
that a total of 10 measurements were used to determine the BP of 
each rat on a single day. Data were collected at weekly intervals 
over the 14-week period.
At the end of 14 weeks, the animals were anaesthetised using 
sodium pentobarbital (160 mg/kg bodyweight) until deep 
anaesthesia indicated by lack of the pedal reflex or blinking when 
touching the eye. The animals were weighed and euthanised by 
exsanguination, and the blood sample was collected in serum 
collection tubes for biochemical analysis. Intraperitoneal fat was 
dissected out and weighed.
Determination of myocardial infarct size
After removal, the rat hearts were arrested in ice-cold Krebs 
Henseleit (KH) medium (in mM: NaCl 119, NaHCO3 25, KCl 4.75, 
KH2PO4 1.2, MgSO4.7H2O 0.6, Na2SO4 0.6, CaCl2.2H2O 1.25, glucose 10) 
and immediately (within 30 s) mounted onto the aortic cannula of a 
perfusion rig. The pulmonary vein was connected to a second 
cannula in order to perform perfusions in the working-heart mode, 
with a preload of 15 cm H2O and an afterload of 100 cm H2O, as 
described previously.8,10 The perfusion medium was continuously 
gassed with 95% O2/5% CO2. The  hearts were fitted with a 
temperature probe and the temperature was  kept constant at 
36.5 °C – 37 °C. After a stabilisation period of 30 min, the rat hearts 
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were subjected to 35 min regional ischaemia by coronary artery 
ligation, followed by reperfusion for 1 h, as described previously.8,10 
Infarct size was determined according to a well-established protocol, 
followed by planimetry, and expressed as the percentage of the 
area at risk.8,10 Planimetry was performed blindly by a third party.
Biochemical analyses
Serum insulin and leptin levels were determined using enzyme-
linked immunosorbent (ELISA) assays (Abcam Ltd, Cambridge, 
UK) according to the manufacturer’s instructions, while 
aldosterone was determined using a Coat-a-Count RIA kit 
(Diagnostics Corporation Ltd, Los Angeles, CA, USA). Both the 
aqueous extract and the serum collected from the animals were 
assayed for Angiotensin 1-Converting Enzyme (ACE) inhibitor 
activity using fluorescence resonance energy transfer (FRET) as 
described by Carmona et al.11 The ACE fluorescent peptide 
substrates specific for the N (Abz-SDK(Dnp)P-OH) and C (Abz-
LFK(Dnp)-OH domains of ACE were obtained from Sigma-
Aldrich. Angiotensin 1-converting enzyme activity of the water 
was tested on aortic endothelial cells in culture.12 Captopril was 
used as a positive control.
Statistical analyses
The changes in BP were analysed by a biostatistician from the 
University of Stellenbosch and are presented with 95% confidence 
intervals. All other data are expressed as mean ± SEM and were 
analysed using GraphPad Prism 6 software by either one-way or 
two-way ANOVA, with p < 0.05 considered as significant.
Results
Biometric measurements
As summarised in Table 5.1, the HFD diet caused significant 
bodyweight gain (449 g ± 13.3 g vs. 377 g ± 8.0 g, p < 0.001 and 
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intraperitoneal (IP) fat (24.3 g ± 2.4 g vs. 8.8 g ± 0.3 g, p < 0.0001) 
gain, while ingestion of buchu resulted in less weight gain in the 
HFD animals – bodyweight 395.8 g ± 13.4 g, p < 0.05 and IP fat 
15.4 g ± 1 g, p < 0.01, having no weight loss effect in control animals. 
This was not accompanied by a difference in food intake but only 
by a slightly reduced buchu water intake in control rats. 
Furthermore, the HFD diet resulted in water retention by the 
animals as evidenced by a significantly smaller 24 h urinary output 
(4.1 mL ± 0.9 mL vs. 11.0 mL ± 0.8 mL). This was not prevented by 
the buchu water ingestion (5.6 mL ± 1 mL). In addition, the well-
known diuretic effect of buchu was only observed in control 
animals (17.5 mL ± 1.6 mL and 16.8 mL ± 1.2 mL, respectively).
Table 5.1 presents a summary of the biometric parameters 
measured in the four groups of animals involved in this study.
Blood pressure measurements
The changes in systolic and diastolic BP observed over the 
course of the experimental protocol are shown in Figure 5.1 
and Figure  5.2. BP was measured at the same time each 
TABLE 5.1: Biometric parameters of four animal groups.
Biometric parameters Control Control + buchu HFD HFD + buchu
Bodyweight (g), n = 15/
group
377.5 ± 8.0 363.4 ± 8.1 449.5 ± 13.3c 395.8 ± 13.4e
IP fat (g), n = 15/group 8.8 ± 0.3 8.6 ± 0.6 24.3 ± 2.4d 15.4 ± 1.0f
Food intake (g/rat/day), 
n = 20/group
21.4 ± 0.5 20.4 ± 0.4 21.7 ± 1.0 19.3 ± 0.7
Water intake (mL/rat/
day), n = 20/group
33.8 ± 0.9 28.7 ± 0.9a 29.7 ± 1.7 30.4 ± 1
Insulin (mIu/mL), 
n = 5/group
16.7 ± 2.7 12.4 ± 3.7 19.6 ± 4.4 16.5 ± 8.4
Urine output 8 wks 
(mL/24 h), n = 10/group
11.3 ± 0.1 17.5 ± 1.6b 9.5 ± 1 7.5 ± 1
Urine output 14 wks 
(mL/24 h), n = 10/group
11.0 ± 0.8 16.8 ± 1.2b 4.1 ± 0.9a 5.6 ± 1g
HFD, high-fat diet; IP, intraperitoneal. 
Note: In addition, by two-way ANOVA – the effect of buchu on weight loss, p = 0.0009; on IP fat, p = 0.004.
ap < 0.05 versus control; bp < 0.01 versus control; cp < 0.001 versus control; dp < 0.0001 versus control; 
ep < 0.05 versus HFD; fp < 0.01 versus HFD; gp < 0.001 versus control + buchu. 
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BP, blood pressure; SBP, systolic blood pressure; HF, high-fat. Type III decomposition Vertical bars denote 
0.95 confidence intervals. Current effect: F(40, 419) = 4.4808, p = 0.0000
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Group Diet = control; Buchu = day 1
Group Diet = control; Buchu = none
Group Diet = HF; Buchu = none
Group Diet = HF; Buchu = day 1
Group Diet = HF; Buchu = week 8
BP, blood pressure; DBP, diastolic blood pressure; HF, high-fat. Type III decomposition Vertical bars denote 
0.95 confidence intervals. Current effect: F(40, 419) = 4.4808, p = 0.0000
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morning by the same person. The animals were trained until a 
stable baseline BP was obtained in all the groups. Data are 
presented showing 95% confidence intervals and were analysed 
and interpreted by a biostatistician from the University of 
Stellenbosch.
Through the monitoring of BP of the animals over the 14-week 
period (intervals 1–10 in the figures), the following was observed: 
1. The HFD diet elevated SBP (157.1 mmHg ± 8.7 mmHg vs. 
122.4 mmHg ± 8.2 mmHg, p < 0.001), reaching significance 
after 4 weeks. Changes in DBP (102.5 mmHg ± 1.3 mmHg vs. 
82.2 mmHg ± 1.4 mmHg, p < 0.0001) showed similar reactions. 
2. In untreated HFD animals, BP increased steadily over the 
14 weeks. 
3. The aqueous extract of buchu prevented the rise in BP 
(SBP 125.9 mmHg ± 12.0 mmHg; DBP 86.2 mmHg ± 13 mmHg at 
week 14).
4. Treating animals from week 8 normalised their BP within 
2  weeks, from 153.1 mmHg ± 8 mmHg to 123.1 mmHg 
± 10.7 mmHg, p < 0.001 (N = 10 in all groups). 
The initial slight rise in BP in HFD animals treated with buchu 
from day 1 did not become significant, and declined to control 
values at week 14. Buchu ingestion had no hypotensive effects in 
control animals.
Infarct size measurement
The cardioprotective effects of treatment with an aqueous 
extract of buchu are demonstrated in Figure 5.3. The diet resulted 
in the development of larger infarcts in the hearts of these 
animals, with a p-value of <0.0001. Furthermore, in both chow-
fed animals and HFD animals, infarct development was 
significantly smaller after ingestion of the buchu water as 
compared to their respective controls. In addition, a two-way 
ANOVA indicated this effect of the buchu water ingestion as 
highly significant, with a p-value of 0.0002.
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Adipokine determination
  Leptin and aldosterone
Serum leptin levels (Figure 5.4) were not significantly elevated in 
the HFD animals. However, ingestion of buchu resulted in significantly 
lower leptin levels in HFD animals. Serum aldosterone levels 
(Figure  5.5) as an indicator of Renin–Angiotensin–Aldosterone 
System (RAAS) activity were significantly elevated in HFD animals 
(619.9 pg/mL ± 136.1 pg/mL vs. 119.24 pg/mL ± 19.1 pg/mL, p < 0.05, 
n = 6), while the ingestion of buchu lowered aldosterone levels in 
the HFD animals to 259.7 pg/mL ± 65.5 pg/mL, p < 0.05, n = 6.
Angiotensin 1-converting enzyme 
inhibitor activity
Using a FRET assay as previously published,12 and commercially 
available fluorescent peptides, we were not able to detect any 
HFD, high-fat diet.
n = 8–18 group
p < 0.0002, *p < 0.05, **p < 0.01, and ***p < 0.0001.
FIGURE 5.3: Hearts of the animals on the control and the HFD were harvested and 
perfused ex vivo. They were perfused in the working mode and subjected to 35-min 





























HFD, high-fat diet. 
Note: Serum was collected upon the euthanising of the animals and analysed as described in the ‘Methods’ 
section. Ingestion of buchu water lowered the serum leptin levels of the HFD animals significantly, while a two-
way ANOVA indicated the effect of buchu water on serum leptin as significant, with a p-value of 0.006, n = 5. 
*p = 0.0158
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HFD, high-fat diet. 
Note: Serum collected upon the euthanising of the animals was analysed for aldosterone levels as 
described in the ‘Methods’ section. 
n = 5
*p < 0.05
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ACE inhibitor activity in a serial dilution of the buchu water 
(Figure 5.6) nor any elevated ACE inhibitor activity in serum 
collected from the control and HFD animals (Figure 5.7).
Discussion and conclusion
The main findings of this study were that ingestion of the aqueous 
extract of Agathosma, commonly known as buchu, at an 
equivalent human dose of 250 mL/day, was able to both prevent 
and successfully treat hypertension. In addition, the same 
extract demonstrated cardioprotective properties, as shown by a 
significant reduction in infarct size in both HFD and control 
animals. Hypertension, coupled with obesity, was elicited by diet 
CT, C-terminal probe activity; NT, N-terminal probe activity; Bckg, background fluorescence; Non, negative 
control; Non + Cap, positive control; 3.85–15.4 = serial dilutions of the buchu water with distilled water.















































































manipulation in male Wistar rats. To date, as reviewed by Rahimi 
et al. and Forouzanfar et al., hypertension is still the leading risk 
factor for mortality and morbidity worldwide.13,14
As already indicated by data from the NHANES III15 report, there 
is a positive relationship between abdominal obesity and 
development of hypertension and, as summarised by Poirier in 
2006 on behalf of the American Heart Association, this further 
increases the risk of mortality from CVD as well as renal disease.16
The profile of changes observed in this study included elevated 
aldosterone levels (Figure 5.5). In the literature, activation of the 
RAAS has been linked with obesity-related hypertension both in 
animal models and humans. As reviewed by Stiefel et al., this is a 
multifactorial relationship, including effects on insulin sensitivity, 
oxidative stress, vascular reactivity and water and salt retention 
or excretion.17 The adipokine leptin is also described as a possible 
HFD, high-fat diet; C, control. 
Note: After euthanasia of the control (C) or obese (HFD) animals with or without buchu treatment, blood 
was collected and serum was stored. The serum was tested for possible enhanced ACE inhibitor activity 
using endothelial cells in culture and probes against both the N (Nte domain) and the C (Cte domain) 
terminal of the ACE enzyme.























































Anti-hypertensive and cardioprotective effects of buchu
86
link between obesity and hypertension.18,19,20 In addition, it was 
shown both in vitro and in vivo that leptin, besides its central 
actions, directly affects the production of aldosterone by acting 
on leptin receptors in the rat adrenal glomerulosa.20,21 
We  acknowledge that this effect was more pronounced in 
female  mice than in male mice. In the latter, leptin seemed to 
exert  anti-hypertensive effects via a central mechanism.22 
However, Huby et al. also demonstrated that adrenocortical cells 
in culture dose-dependently increase aldosterone production 
when stimulated with leptin.23
In view of the significantly lower weight and IP fat gain that we 
documented with ingestion of buchu, we argue that this resulted 
in significantly lower leptin levels observed (Figure 5.4), which, 
in turn, resulted in lower aldosterone production. The observation 
that food intake was not affected corroborates the observation 
that leptin resistance in obesity desensitises this central effect 
of the hormone while not affecting its effects on aldosterone 
secretion.20
A contrasting observation was that ingestion of buchu water, 
despite significantly lowering aldosterone levels, did not lower 
water retention in the HFD rats. As we did not measure anti-
diuretic hormone (ADH) levels, the counter-regulatory hormone 
on water retention, it is possible that this is still a mechanism that 
may be explored. Furthermore, the expression or activity of the 
SGLT2 glucose transporter was not measured. The SGLT2 glucose 
transporter is responsible for the reabsorption of ~90% of the 
glucose in the plasma, while SGLT1 is responsible for the remaining 
10% glucose being excreted in the urine. SGLT2 has a low 
Michaelis–Menten constant (Km) for glucose, therefore a high 
affinity, and is a sodium co-transporter transporting glucose into 
the cells from the tubular lumen. Gluts then transport the glucose 
back into the blood. It is known that the SGLT2 transporter is 
upregulated in obesity and type 2 diabetes mellitus.24 It is 
therefore possible that this was also the case in our model of 
obesity-hypertension. If such a high expression is not rectified by 
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the treatment, water retention would still be observed despite 
the lower aldosterone levels. The levels of vasoconstrictive 
molecules, for example, endothelin-1, were also not measured, 
although the contractile responses of aortic tissue to 
phenylephrine contraction followed by acetylcholine relaxation 
ex vivo were studied, which showed no significant differences 
between control and HFD animals.
Many phytochemicals have anti-hypertensive properties, for 
example, extra virgin olive oil was shown to affect kidney 
angiotensinase, thereby attenuating the diet-induced rise in BP in 
spontaneously hypertensive rats.6,25 Phytochemicals may also act 
as diuretics or ACE inhibitors.26 As three of the main polyphenols 
found in the aqueous extract of buchu may have ACE inhibitor 
activity, we tested whether such activity may be involved in the 
lower aldosterone levels. However, as shown in Figure 5.6 and 
Figure 5.7, we could not detect this as an anti-hypertensive 
mechanism.
At least two of the polyphenols in the buchu water may have 
assisted in the lower weight gain observed, namely the citrus 
flavonoid hesperidin and the flavonoid quercetin. Hesperidin has 
been identified as a treatment option for dyslipidemia,27 while 
quercetin is well known as an anti-obesity treatment.28, 29 In 
addition, quercetin was recently the focus of a meta-analysis 
of clinical trials, where this systematic review highlighted a 
significant effect of quercetin supplementation on lowering BP.30
As buchu has the FDA approval for use in the food industry, 
we conclude from this study that the ingestion of this aqueous 
extract may act as a readily accessible anti-hypertensive 
treatment that should be further evaluated. However, the 
complexity of plant extracts in the treatment of a multifactorial 
disease, as eloquently addressed by Fernandez-Arroyo,5 should 
always be kept in mind. In addition, the possible effects of buchu 
treatment on the intestinal microbiome, as discussed in Chapter 
3, should also be considered as a mediator of observed actions.
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The chapters presented in this book summarise both the in vitro 
and in vivo health-promoting effects of a specific aqueous extract 
obtained from Agathosma. These effects were demonstrated 
either by exposing different cells to the extract or by animals 
ingesting the extract. The dose used in the treatment of the 
animals was equivalent to a human weighing approximately 70 kg 
drinking 250 mL/day of the extract.
Cell-based studies corroborated previous findings of anti-
inflammatory effects but, most importantly, pointed to possible 
metabolic effects that may lead to improved glucose 
homeostasis. These effects were observed both in liver cells and 
in adipocytes. This observation was further elaborated in the 
animal-based studies which showed that this aqueous extract 
of buchu had profound effects not only on the fat depots of 
obese, insulin-resistant animals, causing weight loss, but also 
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anti-hyperglycaemic effects. These effects were demonstrated 
by different research teams from different laboratories over the 
course of more than 5 years. Different diet regimes were used to 
induce obesity and a  pre-diabetic state, but the main findings of 
metabolic change held true. The ingestion of the buchu water 
furthermore caused changes in pancreatic transcription factors 
of the diabetic animals, indicating possible redifferentiation of 
the cells from a diabetic profile to a healthy profile. This is one 
of the novel findings of these studies. However, as stated 
previously, it must be cautioned that the pancreatic biochemistry 
of a rat differs from that of a human and that these results need 
to be confirmed in clinical trials.
In addition to the above effects, animal-based studies showed 
that the buchu water has anti-hypertensive properties as it 
effectively lowered the BP of hypertensive animals. In conjunction 
with this, it was also cardioprotective in different models of 
obesity and insulin resistance, where the hearts of the animals 
were compromised because of their obesogenic diet. The buchu 
water ingestion protected the hearts of the animals against an 
ischaemic incident (a simulated heart attack), with resultant less 
tissue damage afterwards.
An important observation of these studies is that no 
detrimental effects whatsoever were observed. Normal animals 
did not become hypoglycaemic on ingestion of the buchu water, 
nor did their BP fall. They, however, also lost some intraperitoneal 
fat and presented with lower levels of liver cholesterol and 
triglycerides – all health-promoting effects.
At the end of this journey with the product, we can therefore 
conclude that the ingestion of buchu water is safe and promotes 
an improved health status on all accounts tested. Limitations of 
the presented results lie in the shortfall of data obtained in human 
trials, although this is a product that is widely consumed by 
humans in different forms.
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`
The aim of this book was to provide scientific evidence for the many 
anecdotal reports on the beneficial health effects of an aqueous extract 
from leaves of the Agathosma (buchu) plant. The medicinal properties 
of buchu that were focused on in the past include the antimicrobial and 
anti-inflammatory activities of buchu oil in particular. Recently, a byproduct 
of the oil extraction process, namely buchu water, which contains the 
more water-soluble molecules, was investigated by two well-established 
research groups at the University of Stellenbosch to scientifically validate 
its suggested health promoting properties. LC-MS analysis of buchu water 
showed that it contained compounds such as hesperidin, rutin, diosmin, 
quercetin, pulegone and a number of unknown structures which could all 
contribute to its biological activity. Using in vivo and in vitro experimental 
approaches, professors Huisamen, Bouic and co-workers demonstrated the 
anti-diabetic, anti-obesity and anti-hypertensive properties of an aqueous 
buchu extract. These studies form the foundation for further studies in the 
identification of the active compound(s), which, in turn, may have significant 
clinical implications.
Prof. Amanda Lochner, Department of Biomedical Sciences, 
Faculty of Medicine and Health Sciences, University of Stellenbosch, 
Tygerberg, South Africa.
This work is novel, innovative, and makes use of a natural and local plant 
which is relevant to the South African context. The promising findings of 
this work contribute to the growing body of knowledge of this herb and its 
efficacy in the animal model, primarily, with some preliminary work in human 
cell lines. This work is important and needs to be progressed into human 
randomised controlled trials in order to establish its efficacy in the human 
population group. Hopefully this founding work will be used as a strong 
platform for future rigorous trials. It is pleasing to see that herbs and natural 
remedies that have been in existence for a long time are being studied under 
rigorous research conditions. The science of buchu needs to be progressed 
rather than dismissed as fringe medicine supported only by anecdotal 
evidence. This work makes an important contribution to the field of herb and 
plant-based science and its efficacy in managing health and disease. 
Dr Caryn Zinn, School of Sport and Recreation, Faculty of Health and 
Environmental Sciences, Auckland University of Technology, 
Auckland, New Zealand.
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